Proteomic and Lipidomic Profiling of Immune Cell-Derived Subpopulations of Extracellular Vesicles

Proteomics

WILEY-VCH

Proteomics
Proteomics and Systems Biology

RESEARCH ARTICLE OPEN ACCESS

Proteomic and Lipidomic Profiling of Immune Cell-Derived Subpopulations of Extracellular Vesicles

Anna Lischnig[1] | Nasibeh Karimi[1] | Per Larsson[2,3] | Karin Ekström[4] | Rossella Crescitelli[4] | Anna-Carin Olin[3] | Cecilia Lässer[1]

[1]Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden | [2]Chalmers Mass Spectrometry Infrastructure, Department of Life Sciences, Chalmers University of Technology, Gothenburg, Sweden | [3]Occupational and Environmental Medicine, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden | [4]Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Correspondence: Cecilia Lässer (cecilia.lasser@gu.se)

Received: 30 June 2025 | **Revised:** 6 December 2025 | **Accepted:** 10 December 2025

Keywords: exosomes | extracellular vesicles | lipid composition | microvesicles | protein cargo

ABSTRACT

Extracellular vesicles (EVs) are heterogeneous and play important roles in intercellular communication, contributing to physiological and pathological processes. Since few markers currently exist to differentiate subtypes of EVs, this study aimed to determine proteomic and lipidomic differences among four EV subpopulations. Large and small EVs (L-EVs and S-EVs) were isolated from human mast cells (HMC-1) and monocytes (THP-1) by differential ultracentrifugation and then further separated by density cushions into two different densities [low-density (LD) and high-density (HD)]. L-EVs were pelleted at 16,500 × *g*, and S-EVs were pelleted at 118,000 × *g*. LD EVs were collected at 1.079–1.146 g/mL, while HD EVs were collected at 1.146–1.185 g/mL. The morphology, size and yield of EVs were determined by TEM and western blot. The proteome and lipidome of the EV subpopulations were determined with mass spectrometry. A total of 5364 proteins were quantified, and L-EVs LD were enriched in mitochondrial proteins such as TIMM/TOMM and MICOS proteins, while L-EVs HD were enriched in cytoskeleton- and cytokinesis-associated proteins, such as KIF proteins. S-EVs LD were enriched in tetraspanins, ADAM10 and ESCRT machinery proteins, while S-EVs HD were enriched in proteins commonly viewed as contaminants, such as histones, complement factors and collagen. Proteins involved in membrane trafficking between the plasma membrane and organelles, such as adaptor protein complexes, the conserved oligomeric Golgi complex, the trafficking protein particle complex, sortin-nexins, TBC1 domain proteins and coatomer subunits, were expressed at similar levels across all EV subtypes. Furthermore, 107 lipids were quantified, and phosphatidylethanolamine (PE) was less abundant in L-EVs LD as compared to the other EV subtypes, while ceramides were enriched in L-EVs as compared to S-EVs.This study demonstrates that there is a core proteome and lipidome that is similar across all four EV subtypes, but importantly, it also shows that a portion of the proteome and lipidome differs in EV subpopulations separated based on size and density. We suggest that these could be important markers in future EV studies and that they may reflect a different biogenesis and EV function.

Significance of the Study

Cells release subpopulations of extracellular vesicles (EVs) with distinct biogenesis and functions; hence, EVs are a heterogeneous group of vesicles. Currently, few protein markers exist to differentiate subpopulations of EVs, and even fewer studies have compared the lipid content of different subpopulations of EVs. We have here used quantitative mass spectrometry to determine the proteome and lipidome of four subpopulations of EVs of varying sizes and densities. Our study identifies both subtype-enriched proteins and lipids, as well as proteins and lipids that are similarly expressed in two or more EV subtypes. Detailed characterisation of the protein and lipid cargo within EV subpopulations is essential for advancing EV research across a range of biomedical applications. Defining specific molecular markers can provide deeper insights into EV biology, support the discovery of clinically relevant biomarkers and EV-based therapeutics, and enhance the evaluation of EV isolation and purification strategies, particularly when a single EV subpopulation is the primary focus.

Extracellular vesicles (EVs) subtypes in this study

- **L-EVs LD**: Large EVs low-density—pelleted at 16,500 × *g* and then collected at the density of 1.079–1.146 g/mL
- **L-EVs HD**: Large EVs high-density—pelleted at 16,500 × *g* and then collected at the density of 1.146–1.185 g/mL
- **S-EVs LD**: Small EVs low-density—pelleted at 118,000 × *g* and then collected at the density of 1.079–1.146 g/mL
- **S-EVs HD**: Small EVs high-density—pelleted at 118,000 × *g* and then collected at the density of 1.146–1.185 g/mL

1 | Introduction

Extracellular vesicles (EVs) are small lipid membrane-bound particles released by cells that play critical roles in intercellular communication by transporting proteins, lipids and nucleic acids between cells [1]. EVs have been shown to play a role in a variety of biological processes including homeostasis, inflammation, neurodegenerative diseases and cancer [2, 3]. In addition, EVs are studied for their clinical use as biomarkers and therapeutic vehicles for several diseases [4, 5]. Large-scale studies of EV composition and cargo are therefore pivotal for understanding the complex biological functions and mechanisms of EVs.

EVs is an umbrella term for several different subpopulations of vesicles, including, but not limited to exosomes, microvesicles and apoptotic bodies, which differ in size, biogenesis and function [6]. However, their nomenclature remains inconsistent, and most isolation protocols cannot distinguish EVs based on biogenesis, yet those terms are still applied. Therefore, we used the terms large EVs (L-EVs) for EVs isolated at 10,000–20,000 × *g* and the term small EVs (S-EVs) for vesicles isolated at centrifugation forces above 100,000 × *g* to describe the EV subpopulations of this study and the studies we reference. Although several proteomics studies have examined the protein content of S-EVs, less is known about L-EVs. Comparisons of multiple EV subpopulations within the same study are even rarer. This has led to a knowledge gap regarding subpopulation-specific proteins. The characterisation of the content and cargo of EV subpopulations is crucial for advancing EV research across a variety of applications. These markers can enhance our understanding of EV biology, aid in the discovery of biomarkers and improve the characterisation of EV isolation and purification processes.

Lipids not only serve as structural components of cell and vesicle membranes and as energy stores but also function as signalling molecules [7]. Although the lipid content of EVs is as important as their protein content for understanding biogenesis and function, few comprehensive lipidomic EV subpopulation studies have been conducted. The aim of this study is therefore to determine and compare the proteome and lipid composition of four subpopulations of EVs. Undertaking this will allow us to determine which proteins and lipids are uniquely expressed in certain subpopulations and which are common among EV subtypes.

Here, we present an in-depth analysis of the proteomes and lipidomes of four EV subpopulations with different sedimentation properties from human mast cells (HMC-1) and monocytes (THP-1). Four different sample types, namely L-EVs low density (LD), L-EVs high density (HD), S-EVs LD and S-EVs HD, were isolated using a combination of differential ultracentrifugation (16,500 × *g* for L-EVs and 118,000 × *g* for S-EVs) and subsequent density cushion centrifugation [1.079–1.146 g/mL for low-density (LD) and 1.146–1.185 g/mL for high-density (HD)]. Then we characterised the EV subtypes regarding their purity, morphology, yield and cargo. The analysis of the proteome by TMT-LC-MS/MS revealed the differential expression of several proteins and protein groups in the different EV subtypes. The analysis of the lipidomes showed differences in the relative abundance of lipid classes and single lipids.

2 | Material and Methods

2.1 | Cell Cultures

The mast cell line HMC-1 [8, 9] was cultured in Iscove's Modified Dulbecco's Medium (IMDM; Cytiva, HyClone laboratories, Inc., and Gibco, Thermo Fisher Scientific Inc.) supplemented with 1.2 mM 1-Thioglycerol (Sigma–Aldrich). The monocyte cell line THP-1 [10] was cultured in RPMI 1640 Medium (Cytiva) supplemented with 0.05 mM 2-Mercaptoethanol (Gibco). Additionally, all media were supplemented with 10% EV-depleted foetal bovine serum (FBS; Sigma–Aldrich), 100 units/mL penicillin (Cytiva), 100 µg/mL streptomycin (Cytiva) and 2 mM L-glutamine (Cytiva). The FBS was depleted of EVs by ultracentrifugation at 118,000 × g_{avg} with a Type 45 Ti fixed-angle rotor (*k*-factor 178; 38 800 rpm, Beckman Coulter) for 18 h at 4°C. The EV-depleted FBS was sterile filtered through a 0.22 µm filter (Sarstedt AG & Co.) before being added to the media. The incubator was humidified and set to 37°C with 5% CO_2. Cells were seeded at 5 × 10^5 cells/mL, and the cells were cultured for 3–4 days before EVs were isolated.

2.2 | Enrichment of Large and Small EVs by Differential Ultracentrifugation

EVs were isolated from HMC-1 and THP-1 conditioned cell culture medium by differential ultracentrifugation (Figure 1A). For each isolation, 600 mL of conditioned cell culture medium was used. All centrifugation steps were performed at 4°C. First, the medium was sequentially centrifuged for 20 min at 300 × *g* and 20 min at 2000 × *g* to pellet the cells, cell debris and apoptotic bodies. Next, the supernatant was centrifuged for 20 min at 16,500 × g_{avg} with a Type 45 Ti fixed-angle rotor (*k*-factor 1277; 14,500 rpm). Hereafter, this pellet is referred to as crude L-EVs. The supernatant was then used for the final ultracentrifugation at 118,000 × g_{avg} for 2.5 h with a Type 45 Ti fixed-angle rotor (*k*-factor 178; 38,800 rpm). Hereafter, this pellet is referred to as crude S-EVs. All pellets were resuspended with phosphate-buffered saline (PBS) and stored at −80°C.

2.3 | Enrichment of Low-Density and High-Density EVs by Density Cushion Centrifugation

The crude L-EVs and S-EVs were purified on bottom-loaded density cushions, and EVs at two different densities were collected (Figure 1A and Figure S1). The densities at which the EV subtypes were isolated were chosen based on previous experiences [4, 11, 12]. Briefly, the crude EV samples of two to three crude EV isolations were pooled (a total of 1200 or 1800 mL), and PBS was added to reach a total volume of 1.5 mL. This was then mixed with 2.5 mL 60% iodixanol (OptiPrep, Merck). The 4 mL sample/iodixanol mix with an iodixanol concentration of 37.5% was loaded at the bottom of the tube (Open-Top Thinwall Ultra-Clear Tube, 13.2 mL, 14 × 89 mm, Beckman Coulter). Then 2.65 mL of 32%, 2.65 mL of 24%, followed by 2.65 mL of 10% iodixanol solution, was layered on top. The cushion was centrifuged at 180,000 × g_{avg} (SW 41 Ti rotor, *k*-factor 145, 38,000 rpm) for 2 h at 4°C. After the centrifugation, the interphases between the 10% and 24% iodixanol layer (1.079–1.146 g/mL) and the interphase between the 24% and 32% iodixanol layer (1.146–1.185 g/mL) were collected, these fractions are referred to as LD and HD fractions hereafter, respectively. The proteomic analysis was made on three biological replicates, and the lipidomic analysis was made on four biological replicates. Due to the limited amount of EVs in the final samples, no sample was used for both proteomic analysis and lipidomic analysis.

2.4 | Characterisation of EVs

2.4.1 | Protein Measurements

The Pierce BCA Protein Assay Kit (Thermo Scientific) was used according to the manufacturer's instructions. Samples were measured in Clear Flat-Bottom Immuno Nonsterile 96-Well Plates (Thermo Fisher Scientific) using a Varioskan LUX microplate reader (SkanIt Software 4.1 for Microplate Readers RE, ver. 4.1.0.43).

2.4.2 | Western Blot

The EV samples were thawed and diluted, with 6 µg of protein loaded for all samples. Subsequently, 4× Laemmli buffer (Bio-Rad Laboratories) was added to the samples. For samples requiring reducing conditions, 100 µL of β-mercaptoethanol was added to 900 µL of 4× Laemmli buffer. The samples were denatured at 95°C for 5 min before loading onto Mini-Protean TGX precast 4%–20% gels (Bio-Rad Laboratories). As a molecular weight marker, 4 µL Precision Plus Protein WesternC Blotting Standard (Bio-Rad Laboratories) was used. The proteins were separated at 180 V for about 45 min. Blotting onto PVDF membranes was performed on the Trans-Blot Turbo Transfer system (Bio-Rad Laboratories) set to 1.3 A and 25 V for 7 min using transfer buffer [100 mL Trans-Blot Turbo stock solution (Bio-Rad Laboratories), 100 mL ethanol and 300 mL distilled water]. The membranes were blocked with EveryBlot Blocking Buffer (Bio-Rad Laboratories) for 5 min and then incubated with the primary antibodies (Table 1) diluted in EveryBlot Blocking Buffer overnight at 4°C.

After primary antibody incubation, the membranes were washed three times with TBS (Bio-Rad Laboratories) supplemented with 0.05% Tween 20 (TBS/Tween 20). Membranes were incubated with the secondary antibodies (Table 2) and Precision Protein StrepTactin-HRP Conjugate (1:10,000; Bio-Rad Laboratories) diluted in EveryBlot Blocking Buffer at RT for 1 h. After incubation, the membranes were washed four times in TBS/Tween 20. The blots were imaged with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) and the ChemiDoc Imaging System (Bio-Rad Laboratories). The secondary antibodies and StrepTactin-HRP were evaluated for unspecific binding to the samples in reducing and nonreducing conditions.

2.4.3 | Transmission Electron Microscopy

For negative staining, formvar/carbon-coated nickel grids (Ted Pella, Inc.) were glow discharged before incubation with 5 µg of EVs for 5 min. Grids were washed two times with H_2O. Samples were then fixed with 2% glutaraldehyde for 10 min before being negative stained with 2% uranyl acetate for 1.5 min. The grids were then dried well before being acquired using a Talos L120C transmission electron microscope (Thermo Fisher Scientific) at 120 kV with a CCD camera.

For each of the sample types, two biological replicates were prepared on grids for imaging. Approximately a total of 22 images were acquired from three different positions on each grid. EVs were counted, and the longest diameter of each EV was measured using Fiji ImageJ 2.14.0/1.54f [13]. Sample preparation, image acquisition and measurement of EVs were conducted in a blinded manner. That is the operator who acquired the images and measured the EVs was blinded to which sample was which. This was to avoid bias towards capturing pictures or measuring vesicles of a certain size, depending on knowing which sample was analysed. The total amount of EVs measured for each EV subtype is listed in Table 3.



FIGURE 1 | Characterisation of four subpopulations of EVs isolated from immune cells. (A) Schematic overview of the isolation protocol, including both differential ultracentrifugation and a density cushion. Image 1A was created by BioRender.com with permission. (B, C) Five micrograms of vesicles were loaded onto grids, negative stained and evaluated by transmission electron microscopy. Representative micrographs are shown from HMC-1 (B) and THP-1 (C). The scale bars represent 500 nm. Samples from three biological replicates were evaluated for each cell line. (D, E) For each vesicle subtype, 41–45 micrographs were acquired. All structures in the micrographs were manually measured (Table 3). In total, the diameters of over 8500 and 5000

TABLE 1 | Primary antibodies used for western blot.

Protein	Clone	Number	Supplier	Host	Condition	Dilution
CD81	M38	ab79559	Abcam	Mouse	Not reducing	1:1000
CD63	H5C6	556019	BD Pharmingen	Mouse	Not reducing	1:1000
CD9	MM2/57	CBL162	EMD Millipore	Mouse	Not reducing	1:1000
Calnexin	C5C9	2679	Cell Signalling Technology	Rabbit	Reducing	1:1000
Flotillin-1	EPR6041	ab133497	Abcam	Rabbit	Reducing	1:1000
Mitofilin	EPR8749	ab137057	Abcam	Rabbit	Reducing	1:1000
TOMM20	EPR15581-54	ab186735	Abcam	Rabbit	Reducing	1:2000

TABLE 2 | Secondary antibodies used for western blot.

Antibody	Clonality	Number	Supplier	Host	Dilution
Anti-rabbit IgG	Polyclonal	NA9340V	GE Healthcare UK Limited	Donkey	1:5000
Anti-mouse IgG	Polyclonal	NA9310V	GE Healthcare UK Limited	Sheep	1:5000

TABLE 3 | Number of vesicles measured with TEM.

	HMC-1				THP-1			
EV type	L-EVs LD	L-EVs HD	S-EVs LD	S-EVs HD	L-EVs LD	L-EVs HD	S-EVs LD	S-EVs HD
Number of images	44	44	45	44	43	42	45	41
Number of EVs	1263	852	4044	2358	1516	664	1615	1279

2.5 | Proteomics

2.5.1 | Experimental Design and Sample Generation

For tandem mass tag (TMT)–liquid chromatography (LC)–tandem mass spectrometry (MS/MS), three independent biological replicates were used for each of the four sample types resulting in 12 samples per cell line and 24 samples in total ($n = 3$ for each vesicle type and cell line). The starting volume of cell culture media for each biological replicate was 1200 or 1,800 mL, but the amount of EV used was normalised to 40 μg of protein per sample. The TMT method used allowed the comparison of up to 16 samples in one set. Therefore, the 12 samples for each cell line were run on two different sets. Proteomic analysis was performed at the Proteomics Core Facility at Sahlgrenska Academy, University of Gothenburg, Sweden.

2.5.2 | Protein Digestion and Labelling

Aliquots containing 40 μg of each sample (except 35 μg protein for HMC-1 L-EVs HD-2), and two reference pools made up of aliquots from each sample, were digested with trypsin using the filter-aided sample preparation (FASP) method [14]. Briefly, the samples were reduced with 100 mM dithiothreitol at 56°C for 30 min. Samples were diluted to 1:3 with 8 M urea in 50 mM triethylammonium bicarbonate (TEAB), transferred onto Microcon-30 kDa Centrifugal Filter Units (Merck) and washed four times by adding 200 μL of 8 M urea in 50 mM TEAB, two times with digestion buffer [0.5% sodium deoxycholate (SDC), 50 mM TEAB] and subsequent centrifugation at 10,000 × *g*. Free cysteine residues were modified using 10 mM methyl methanethiosulfonate (MMTS) solution in digestion buffer for 20 min at RT, and the filters were then repeatedly washed with

structures were measured in HMC-1 (D) and THP-1 (E), respectively. Two biological replicates were analysed per EV type. Statistical analysis by one-way ANOVA. $^{**}p = 0.0012$, $^{***}p = 0.0005$, $^{****}p < 0.0001$. (F–I) Western blot was used to investigate the presence of markers generally enriched in all EVs (F), markers generally enriched in L-EVs (G), markers generally enriched in S-EVs (H) and markers generally not enriched in EV (I). A total of 6 μg was loaded per sample. $N = 1$. EV, extracellular vesicle; HD, high density; HMC-1, human mast cells; LD, low density; L-EVs, large extracellular vesicles; S-EVs, small extracellular vesicles; THP-1, human monocytes.

100 µL of digestion buffer. Pierce trypsin protease (MS Grade, Thermo Fisher Scientific) in digestion buffer was added at a ratio of 1:100 relative to total protein mass, and the samples were incubated at 37°C overnight. Next morning, another portion of trypsin (1:100) was added and the mixture was incubated at 37°C for 4 h. The peptides were collected by centrifugation and labelled using TMTpro 16-plex isobaric mass tagging reagents (Thermo Scientific) according to the manufacturer's instructions. Samples from each cell line were labelled in separate sets and combined into two sets together with one reference sample. Acetonitrile was evaporated using vacuum centrifugation, and SDC was removed by acidification with 10% TFA with subsequent centrifugation. The pooled samples were purified using High Protein and Peptide Recovery Detergent Removal Spin Column (Thermo Fisher Scientific) according to the manufacturer instructions, followed by Pierce Peptide Desalting Spin Columns (Thermo Scientific), following the manufacturer's instructions.

The combined labelled sample was fractionated into 34 primary fractions by basic reversed-phase chromatography (bRP-LC) using a Dionex Ultimate 3000 UPLC system (Thermo Fischer Scientific). Peptide separations were performed on a reversed-phase XBridge BEH C18 column (3.5 µm, 3.0 × 150 mm, Waters Corporation) using a gradient from 8% to 40% Solvent B over 48 min, 40%–50% over 10 min, followed by an increase to 100% B over 5 min, at a flow of 400 µL/min. Solvent A was 10 mM ammonium formate buffer at pH 10.00, and Solvent B was 90% acetonitrile, 10% 10 mM ammonium formate at pH 10.00. The primary fractions were concatenated into final 17 fractions (1 + 18, 2 + 19, … 17 + 34), evaporated and reconstituted in 15 µL of 3% acetonitrile and 0.2% trifluoroacetic acid.

2.5.3 | LC-MS/MS Analysis

Each fraction was analysed on an Orbitrap Fusion Tribrid mass spectrometer interfaced with an Easy-nLC 1200 nanoflow LC system (both—Thermo Fisher Scientific). Peptides were trapped on the Acclaim Pepmap 100 C18 trap column (75 µm × 2 cm, particle size 5 µm, Thermo Fischer Scientific) and separated on the in-house packed C18 analytical column (75 µm × 37 cm, particle size 3 µm) using the gradient from 5% to 12% B over 5 min, 12% to 35% B over 70 min followed by an increase to 100% B for 5 min, and 100% B for 10 min at a flow of 300 nL/min. Solvent A was 0.2% formic acid, and Solvent B was 80% acetonitrile, 0.2% formic acid. The quantitative analysis was performed in multinoch MS3 mode, and the precursor ion mass spectra were recorded at 120,000 resolution, the most intense precursor ions were selected ('top speed' setting with a duty cycle of 3 s), fragmented using CID at collision energy setting of 30, spectra and the MS/MS spectra were recorded in ion trap with the maximum injection time of 50 ms and the isolation window of 0.7 Da. Charge states 2–7 were selected for fragmentation, dynamic exclusion was set to 45 s with 10 ppm tolerance. MS3 spectra for reporter ion quantitation were recorded at 50,000 resolutions with HCD fragmentation at a collision energy of 55 using the synchronous precursor selection of the 10 most abundant MS/MS fragments, with the maximum injection time of 120 ms.

2.5.4 | Database Search and Quantification

Identification and relative quantification were performed of the combined injections using Proteome Discoverer version 2.4 (Thermo Fisher Scientific). The database search was performed using the Mascot search engine v. 2.5.1 (Matrix Science, London, UK) against the Swiss-Prot human database. Trypsin was used as a cleavage rule with no missed cleavages allowed; methylthiolation on cysteine residues, TMTpro at peptide N-termini and on lysine side chains were set as static modifications, and oxidation on methionine was set as a dynamic modification. Precursor mass tolerance was set at 5 ppm and fragment ion tolerance at 0.6 Da. A percolator was used for the peptide-spectrum match (PSM) validation with a strict false discovery rate (FDR) threshold of 1%. Quantification was performed in Proteome Discoverer 2.4. The TMT reporter ions were identified with 3 mmu mass tolerance in the MS3 HCD spectra, and the TMT reporter S/N values for each sample were normalised within Proteome Discoverer 2.4 on the total peptide amount. Only the quantitative results for the unique peptide sequences with the minimum SPS match % of 50 and the average S/N above 10 were taken into account for the protein quantification.

2.5.5 | Statistics and Bioinformatics

For the analysis of the quantified proteins, the significance was calculated by paired Student's *t* test on logged values. Subsequently, GraphPad Prism 10 was used to create the volcano plots. Qlucore Omics Explorer (Qlucore Omics Explorer Version 3.9) was used for principal component analysis (PCA). After identifying the uniquely enriched proteins in the different EV subtypes, the Database for Annotation, Visualisation and Integrated Discovery [DAVID; https://david.ncifcrf.gov/home.jsp (accessed: August 22, 2024)] was used to determine the most enriched cellular compartments associated with these proteins. Revigo was used in November 2025 to summarise the GO Terms into networks [15], and Cytoscape (Version 3.10.4) was used to visualise the networks [16].

The proteins from the five MISEV categories were created based on in the MISEV2023 guidelines [17] and analysed and visualised with Qlucore Omics Explorer (Qlucore Omics Explorer Version 3.9), and multigroup (ANOVA) comparisons displayed as hierarchical clustering heat maps. Details of the analysis, such as the *p* values, *q* values and number of proteins included in the analysis, are listed in Table S1.

Seven previously published studies were used to create two lists of proteins [11, 18–23]. One list for proteins enriched in S-EVs and one list for proteins enriched in L-EVs. Details of the analysis, such as the *p* values, *q*values and number of proteins included in the analysis, are listed in Table S1.

The list of common EV proteins were created based on Top100 proteins in VesiclePedia (accessed: August 27, 2024) and Top100 proteins in EVpedia (accessed August 27, 2024). After removing duplicates, the list consisted of 118 proteins. Qlucore Omics Explorer (Qlucore Omics Explorer Version 3.9) was used for

multigroup (ANOVA) comparisons displayed as hierarchical clustering heat maps. Details of the analysis, such as the p values, q values and number of proteins included in the analysis, are listed in Table S1.

2.6 | Lipidomics

2.6.1 | Experimental Design and Sample Generation

Lipid extraction and analysis were performed at the Department of School of Public Health and Community Medicine at Sahlgrenska Academy, University of Gothenburg, Sweden. The lipids analysed and how they were identified are listed in Table S2.

For the lipidomic analysis, four independent biological replicates were used for each of the four sample types, resulting in 16 samples per cell line and 32 samples in total ($n = 4$ for each vesicle type and cell line). The starting volume of cell culture media for each biological replicate was 1200 or 1800 mL, but the amount used was normalised to 10 µL per sample. Additionally, a media-only control was created. Briefly, this was achieved by using media supplemented with 10% EV-depleted FBS. This complete media, which had not been in contact with cells, was processed through the EVs isolation protocol described in Sections 2.2 and 2.3. Hence, we ended up with four media-only controls, one for each subpopulation of EVs.

2.6.2 | Lipid Extraction

A Bligh and Dyer liquid extraction procedure was used to extract the lipids from the EV preparations. Glass tubes (CORNING 99449-13) were prepared with 1 mL dichloromethane (DCM) (EMSURE; Merck), 2 mL methanol (LC-MS grade LiChrosolv; Merck) and 790 µL of 0.9wt% NaCl(aq). To the tubes 10 µL of vesicle sample was added, followed by the addition of internal standards. The internal standard SPLASH LipidoMIX (SKU: 330707, Avanti Polar Lipids, Inc. USA) was used as internal standard for the lipid classes PC/LPC/PE/LPE/SM/PG/PI. The isotope labelled standard GlcCer(d18:1(d5)/18:0) (SKU: 860638, Avanti Polar Lipids, Inc., USA) was used as an internal standard for the ceramide and hexosylceramide lipid classes. The SPLASH stock standard was diluted 200 times in methanol and 20 µL was added to each sample. The GlcCer(d18:1(d5)/18:0) standard was diluted to 0.027 µg/mL in methanol before adding 10 µL to the sample tubes. The tubes were vortexed for 30 s, ultrasonicated for 5 min and put on a shaker for 15 min at RT to solubilise the lipids in the monophase. For phase separation, 1 mL DCM and 1 mL 0.9wt% NaCl(aq) were added to the extraction tubes, final ratio NaCl(aq):MeOH:DCM [1.8:2:2]. The tubes were vortexed for 30 s and centrifuged at 300 × g for 10 min at 10°C to assist the phase separation into two layers. From the lower organic phase 1000 µL was transferred to an Eppendorf tube using a Hamilton syringe (washed 2× in isopropanol and 2× in methanol between samples). The Eppendorf tube was centrifuged at 10,000 × g for 10 min at 10°C to remove particulates. From the Eppendorf tubes, 800 µL of each sample was transferred to an HPLC vial (Waters Total Recovery SKU: 186002805) using a CTC-PAL robot configured with a Hamilton syringe. Then, solvents were evaporated under a stream of nitrogen gas with a temperature of 30°C (Porvair MiniVap Gemini) in the total recovery vial. The remaining lipid film was solvated with 300 µL acetonitrile/isopropanol [ratio (2:1)]. The tubes were vortexed for 30 s, ultrasonicated for 5 min and put on a shaker for 15 min at RT to solubilise the lipids fully in the injection solvent.

2.6.3 | UHPLC-ESI-QqQ-MS/MS Analysis

An initial pre-run was done to determine the optimal dilution for each sample. This was a necessary step due to the large differences in the initial concentrations between samples. The additional dilution step was only necessary for the PC and SM lipid classes. Once the optimal dilutions were determined, the study data were collected using this dilution.

Analysis was performed using Ultra High-Performance Liquid Chromatography (Waters ACQUITY UPLC I-Class PLUS) using Electro Spray Ionisation and a Triple Quadrupole mass detector (UHPLC-ESI-QqQ-MS/MS) (Waters Xevo TQXS). The mass spectrometer was operating in MRM mode (multiple reaction monitoring) for data acquisition.

Chromatography was performed based on two different separation principles: hydrophilic interaction chromatography (HILIC) (BEH Amide VanGuard FIT Column, SKU:186009508) and reverse phase chromatography (RP) (Premier BEH C8 VanGuard FIT Column, SKU:186010360). HILIC method was used for lipids in the classes LPC/PG/PE/SM/PI in order the have chromatographic lipid class separation. PC lipids were analysed on RP due to the large number of species in this class it was desirable to separate them based on the fatty acyl chains. The Cer and HexCer lipids were analysed on the same column and mobile phase as the PC lipids, but with a slightly extended gradient. For details on the chromatography mobile phases and gradients, see Supporting Information data.

Lipid panel for targeted UHPLC-ESI-QqQ-MS/MS method was selected based on previous screening experiments. Targeted screening was conducted using the Waters LipidQuan MRM database containing over 2000 lipids. To verify that no major lipid was missed, additional screening was done using precursor ion scanning for the different lipid class-specific fragments (PIS184, PIS264, NL141, NL189 and NL277).

2.6.4 | Data Analysis and Quantification

Masslynx 4.2 software was used for data acquisition, and Targetlynx was used for peak integration. Integrated peaks were exported to the SAS 9.4 software for quantification. The online tool LICAR was used for isotope correction of coeluting peaks in HILIC [24]. The calculated Type II isotope correction factors were applied to the results to account for the isotopic overlap of lipids that are close in mass and have similar retention time. Quantification was made relatively to the internal standard of the same class. Both the ceramide analytes and the hexosylceramides were quantified using the GlcCer(d18:1(d5)/18:0) internal standard as they have shown to have very consistent and comparable

recoveries. Results were normalised as mol%, meaning that all lipids in a sample were summed up and subsequently expressed as the percentage of the total. Suffix A or B was added to the lipid annotation when isomeric peaks were found, for example, LPC(18:2) SN1/SN2 isomers were annotated as LPC(18:2)_A and LPC(18:2)_B.

2.6.5 | Statistics and Bioinformatics

Qlucore Omics Explorer (Omics Explorer Version 3.9) was used for PCA and multigroup comparisons displayed as hierarchical clustering heat maps. GraphPad Prism 10 was used to display differential enrichment of lipid classes.

2.7 | Nano-Flow Cytometry

The presence of tetraspanins (CD63, CD81, and CD9) and ADAM10 on the surface of EVs was determined utilising a Flow NanoAnalyzer (NanoFCM Inc.) following the manufacturer's guidelines and using a staining protocol as described previously [25, 26]. For experimental design, the MIFlowCyt-EV guidelines were consulted [27, 28]. Controls, including buffer-only controls, buffer with reagent controls, unstained sample controls, single-stained sample controls and detergent treatment, were performed. For the detergent treatment control, stained samples, diluted 10-fold, were treated with Triton X-100 and compared to the non-treated sample, and the ratio of disrupted particles was calculated. In this project, we used 0.1% TritonX-100 and incubation for 5 min at RT [29]. As we could observe positivity for the ADAM10 isotype control with THP-1 EVs, the analysis was only performed on HMC-1 EVs, where the isotype control was negative. The analysis was made on three biological replicates for HMC-1.

2.7.1 | Instrument Setup

The system was calibrated before samples were loaded and analysed. For alignment, a 1:100 dilution of 0.25 μm Fluorescent Silica Microspheres (250 nm Std FL SiNPs) was used at a laser power of 20/50 mW 488 and 20/100 mW 638 at a side scatter (SS) decay of 0.2%. The 250 nm Std FL SiNPs bead data were recorded and analysed as the concentration standard using the large signal auto threshold. S16M-Exo Silica Nanosphere Cocktails were used to create a calibration curve of particle sizes and SS intensity. S16M-Exo includes particles at a range of 68–155 nm (peaks at 68, 91, 113 and 155 nm) and was recorded at a laser power of 10/50 mW 488 and 20/100 mW 638; SS decay of 10% and analysed using the small signal auto threshold. The pressure was kept at 1.0 kPa for all standards and samples.

2.7.2 | Staining

First, the concentration of the EV samples was determined to ensure that the stained samples would have the recommended concentration of 2000 and 12,000 events per minute. Based on these measurements, EV samples were prediluted before antibody staining. Prediluted antibodies (Table 4), isotype controls (Table 5) or PBS were added to 3 μL pre-diluted EV samples to a final volume of 5 μL. The samples were incubated in the dark for 40 min. After incubation, 45 μL PBS (0.0067 M PO_4, pH 7.0–7.2, Cytiva, HyClone Laboratories) was added to the samples, leading to a 10X dilution of the EV-antibody mix. Directly before acquisition, the samples were further serially diluted to reach final dilutions of 100x and 200x before recording on the Flow NanoAnalyzer. Dilutions were done with TE Buffer (Tris-EDTA, 1X Solution, pH 7.4, Molecular Biology, Fisher BioReagents, USA).

2.7.3 | Acquisition

Samples were run at the same sampling pressure as the concentration standard and with the same laser power as the size standards. The sampling pressure was set to 1.0 kPa. The SS was set as the triggering channel (each signal above the SSC threshold was acquired), and samples were analysed using the auto threshold according to the EXO settings.

2.7.4 | Analysis, Statistics and Bioinformatics

The nano-FCM software (NF profession V1.0) was used to calculate the percentage of positive signal, particle concentration and size distribution. To calculate the percentage of positive events, particle concentration and size distribution, the NanoFCM software (NanoFCM Profession V2.0; NanoFCM, Inc.) was used. The auto threshold (small) was set for each sample, and gates were set.

3 | Results

3.1 | Immune Cells Secrete EVs of Different Sizes and Densities

We have previously determined the protein cargo of two EV subpopulations of different sizes released by breast cancer cells [1]. In the current study, we build on these findings by determining the protein and lipid content in four immune cell-derived EV subpopulations. For this purpose, we expanded on the isolation method by incorporating a density cushion that enables the isolation of EV subpopulations according to density. This resulted in the determination of the proteomic and lipidomic profile of four subpopulations of EVs enriched at different sizes and densities.

Conditioned medium was collected from the immune cell lines HMC-1 (mast cells) and THP-1 (monocytes), and crude L-EVs and S-EVs were isolated by differential ultracentrifugation (Figure 1A). Subsequently, a bottom-loaded density cushion centrifugation was used to purify and sub-fractionate the crude samples further. As EVs were collected at two different densities for each crude EV type (Figure S1), this resulted in four types of EVs: L-EVs LD, L-EVs HD, S-EVs LD and S-EVs HD (Figure 1A). The LD EVs were collected in the interphase between 10% and 24% iodixanol (1.079–1.146 g/mL), and HD EVs were collected in the interphase between 24% and 32% iodixanol (1.146–1.185 g/mL). TEM showed that all four EV subtypes indeed contained EVs (Figure 1B, C and Figure S2). To be able to accurately determine

TABLE 4 | Antibodies and their predilutions used for Flow NanoAnalyzer.

Protein	Predilution	Clone	Number	Supplier	Fluorophore
ADAM10 (CD156c)	10	REA309	130-104-406	Miltenyi Biotec	FITC
Tetraspanin mix					
CD9	6	M-L13	341648	BD Biosciences BD Pharmingen	APC
CD63	20	H5C6	561983	BD Biosciences BD Pharmingen	AF647
CD81	6	JS-81	551112	BD Biosciences BD Pharmingen	APC

TABLE 5 | Isotype control antibodies and their predilutions used for Flow NanoAnalyzer.

AB	Isotype control for	Predilution	Clone	Number	Supplier	Fluorophore
REA Control Antibody (S), human IgG1, FITC	ADAM10-FITC	33	REA293	130-113-437	Miltenyi Biotec	FITC
APC Mouse IgG1, κ Isotype Control	CD9-APC and CD81-APC	6	MOPC-21	555751	BD Biosciences BD Pharmingen	APC
AF647 Mouse IgG1, κ Isotype Control	CD63-AF647	20	MOPC-21	557714	BD Biosciences BD Pharmingen	AF647

the different EV sizes in the four subpopulations, we conducted a double-blinded experiment where several thousand EVs were manually annotated (Figure 1D, E). L-EV fractions generally contained a higher amount of bigger EVs than S-EV fractions. Additionally, HD fractions contained EVs that were smaller than the corresponding LD fraction. Notably, L-EVs LD were more heterogeneous in size, and these samples also had fewer non-EV particles than L-EVs HD. Overall, S-EVs were smaller than L-EVs; additionally, more non-EV particles could be seen in these samples. The most notable difference between S-EVs LD and S-EVs HD was the high amount of non-EV particles in the HD factions.

To characterise the four EV subtypes, we evaluated the presence of a general EV marker (flotillin-1), a non-EV protein (calnexin) and markers that have been suggested to be enriched in either S-EVs (CD63, CD9 and CD81) or L-EVs [mitofillin (IMMT) and mitochondrial import receptor subunit TOM20 homolog (TOMM20)] with western blot. All four EV subtypes were positive for flotillin-1 (Figure 1F), which confirms ours and others previous findings in other cell line-derived EVs that all EV subtypes contain flotillin-1 to a similar degree [1, 21]. As expected, mitofillin and TOMM20 showed L-EV enrichment (Figure 1G). The tetraspanins CD9, CD63 and CD81 were present in all fractions; however, an S-EV enrichment could be observed, which was more prominent in the HMC-1 S-EVs (Figure 1H). CD9 was faint in THP-1-derived EVs as compared to HMC-1; however, previous studies have shown different expression of tetraspanins in EVs from different cell types, with CD9 being particularly low in THP-1 EVs compared to other cell lines [30]. A signal for calnexin was mainly detected in THP-1 L-EVs (Figure 1I). These results, together with the TEM results, suggest that we have enriched EVs with different sizes, densities and protein cargo.

3.2 | The Proteomes of the Four EV Subpopulations Are Significantly Different

We performed quantitative proteomics to identify differentially enriched and equally expressed proteins in the four subpopulations of EVs, which were all analysed in biological triplicates for each cell line. In total, 5364 proteins were quantified in our dataset, 3970 and 4736 of these proteins were quantified in HMC-1 and THP-1 cell line-derived EVs, respectively, with 3342 being quantified in both (Table S3). To visualise the relationship between the different types of isolated EVs, a PCA was performed for each cell line, including all proteins. Component 1, representing around 50% of the variability, distinguished L-EVs and S-EVs (Figure 2A, B). Furthermore, Components 2 and 3 distinguished the LD and HD fractions; however, this was more evident in the THP-1-derived EVs as compared to the HMC-1-derived EVs. A similar pattern was observed when all samples from both cell lines were analysed in the same PCA plot, although the samples were then also separated based on the cell type in Components 2 and 3 (Figure 2C).

Firstly, we performed pairwise comparisons between the different EV subtypes, revealing that proteomic differences among EV subpopulations were more pronounced by size than by density (Figure 2D–M). Proteins identified as uniquely upregulated in EV subpopulations (Figure 2N and Figure S3A–C) were analysed with DAVID and Revigo to determine the most enriched biological cellular compartments associated with these proteins



FIGURE 2 | The proteome of the four EV subpopulations is substantially dissimilar. Quantitative proteomics (tandem mass tag) was used to determine the differences in the proteomes of the EV subpopulations. Three biological replicates (40 μg protein/sample) were used from both cell lines. (A–C) Principal component analysis illustrating the relationship between the subpopulations derived from HMC-1 (A), THP-1 (B) and both cell lines combined (C). (D–G) Volcano plots of the proteomes of S-EVs LD, S-EVs HD, L-EVs LD and L-EVs HD from HMC-1 compared with each other. (H) Summary of the numbers of altered proteins in each comparison in D-G. (I–L) Volcano plots of the proteomes of S-EVs LD, S-EVs HD, L-EVs LD and L-EVs HD from THP-1 compared with each other. (M) Summary of the numbers of altered proteins in each comparison in I-L. Dotted lines indicate cutoffs: 1.3 on the *y*-axis (corresponding to $p < 0.05$) and 0.585 on the *x*-axis (corresponding to fold change >1.5). (N) Identification of the proteins that are uniquely enriched in each EV subpopulation. The enriched proteins were produced as described in Supplementary Figure 3. EV, extracellular vesicle; HD, high density; HMC-1, human mast cells; LD, low density; L-EVs, large extracellular vesicles; S-EVs, small extracellular vesicles; THP-1, human monocytes.

(Figure 3A–D). Proteins upregulated in L-EVs LD were associated with mitochondrion, endoplasmic reticulum (ER), nucleus and membrane, while the proteins upregulated in L-EVs HD were associated with cytosol, cytoskeleton, kinesin complex and microtubule (Figure 3A, B). The proteins upregulated in S-EVs LD were associated with the cytoplasm, plasma membrane (PM), and early and late endosome, while the proteins upregulated in S-EVs HD were associated with the nucleus, cytosol, spliceosome and Golgi apparatus (Figure 3C, D). The GO term 'extracellular exosome' was associated with the upregulated proteins for all subpopulations, but had the highest enrichment in S-EVs LD.

Secondly, we analysed proteins that were not altered but showed similar expression across all four EV subtypes in both cell lines. Here, we identified protein groups such as adaptor protein complex subunits (APs), coatomer subunits (COPs), conserved oligomeric Golgi complex subunits (COG), sortin-nexins (SNXs), trafficking protein particle complex subunits (TRAPPCs), TBC1 domain-containing proteins (TBC1Ds) and vacuolar protein sortings (VPSs) belonging to homotypic fusion and vacuole protein sorting (HOPS), class C core endosomal vacuole tethering (CORVET), endosome-associated recycling protein (EARP) and Golgi-associated retrograde protein (GARP) complex (Figure S4A–H). Interestingly, several of these groups of proteins are involved in the transport of vesicles, proteins and membranes between organelles and the PM.

Taken together, L-EVs and S-EVs were well separated; however, the separation between the LD and HD samples was more pronounced for the THP-1 EVs than for the HMC-1 EVs. The four EV subpopulations had a core EV proteome that was not altered between the subpopulations. In addition, the proteins that were differently enriched in the EV types were associated with different biological functions and organelles. Both the PCA plots and the GO term enrichment analysis strengthen the assumption that our four sample types are enriched for different subpopulations of EVs. This indicates that our EV subtypes might have distinct biogenesis and biological functions, which could aid in elucidating the differences between EV subpopulations.

3.3 | Immune Cells Secrete EVs With Different Expression of Common EV Markers

The International Society for Extracellular Vesicles (ISEV) have published three Minimal Information for Studies of Extracellular Vesicles (MISEV) guidelines, MISEV2014, MISEV2018 and MISEV2023 [17, 31, 32]. In the MISEV2018 and MISEV2023, five categories of proteins were presented to be used when analysing the protein content of EVs. Categories 1 and 2 assess the presence of EVs, with Category 4 providing additional information on intracellular origins. Categories 3 and 5 assess the presence of contaminations and coisolates. We analysed all the proteins quantified in our dataset across these five categories. Category 1 assesses the presence of EV membrane proteins from the PM and the endosomal pathway. The majority of the tetraspanins, ADAM10 and some integrins (ITGs) were enriched in S-EVs LD in THP-1 and in both S-EVs in HMC-1, while syndecans and glypicans were enriched in both S-EVs LD and S-EVs HD in both cell lines (Figure 4A). Furthermore, major histocompatibility class I and II, heteromeric G proteins (GNAs), and the rest of the integrins were enriched in both L-EVs LD and S-EVs LD (Figure 4A). Belonging to Category 2 (cytosolic EV-associated proteins), the majority of the ESCRT proteins were enriched in S-EVs LD in THP-1, while this enrichment was not as prominent in HMC-1. Furthermore, SDCBP (syntenin-1) was enriched in both S-EVs LD and S-EVs HD in both cell lines (Figure 4B). Flotillin-1 and -2 were enriched in both L-EVs LD and S-EVs LD, while the tubulins (TUBBs) were either enriched in L-EVs HD or S-EVs HD (Figure 4B). In Category 3 proteins of non-EV coisolated structures are summarised. The 14-3-3 proteins (YWHAs) enrichment was cell-dependent, while TGFB1 was enriched in L-EVs LD in both cell lines. Whereas the rest of the proteins were enriched in S-EVs HD or in both S-EV subtypes (Figure 4C). In Category 4, the proteins associated with mitochondria, ER and Golgi apparatus were enriched in L-EVs LD, while the nucleus proteins such as histones were enriched in S-EVs HD (Figure 4D). Lastly in Category 5, which contains 'secreted proteins recovered with EVs', the majority of proteins were enriched in S-EVs HD, except for IL-18 which was enriched in L-EVs LD and L-EVs HD (Figure 4E). Together, these results demonstrate that the EV-associated proteins (Categories 1 and 2) are mainly associated with S-EVs LD and to some extent L-EVs LD, while the proteins more associated with contamination/coisolates (Categories 3 and 5) are enriched in S-EVs HD. Furthermore, the proteins associated with organelles other than the PM and endosomes (Category 4) are enriched in L-EVs LD, except for histones, which were enriched in S-EVs HD.

Next, we determined the expression of 28 proteins that have previously been suggested to be the core proteome of exosomes by Kugeratski et al., by analysing S-EVs from 14 cell lines [30]. We could only validate six of these proteins: PDCD6IP, SDCBP, HISTIH4A, RAN, RPSA and CLTC to be enriched in either S-EVs LD, S-EVs HD or both compared to L-EVs in both cell types (Figure S5). This demonstrates the limitations of only comparing the proteome of one EV subtype, in this case S-EVs, to the cell proteome. We therefore next constructed a list of previously identified markers for L- and S-EVs, discovered by us and others in seven studies that had performed mass spectrometry analysis comparing L-EVs and S-EVs. Many of the proteins that were previously shown to be enriched in S-EVs as compared to L-EVs were also enriched in S-EVs in our dataset (Figure 5A, B). Many of these proteins are known as classical EV markers and were also included in the MISEV analysis and are therefore discussed in Figure 4. However, there were also several proteins that we could not validate to be enriched in S-EVs, such as ICAM1, CD44, STX3 and ITGA5, but were instead equally or more enriched in L-EVs LD in both cell types. These findings indicate that the distribution of these proteins among EV subtypes may be cell-type dependent, especially since prior work has primarily focused on EVs derived from cancer cells rather than immune cells. However, methodological differences in EV isolation across studies may lead to subtle variations in the enrichment of specific EV subtypes, which may also contribute to this discrepancy.

Similarly, many of the proteins that were previously shown to be enriched in L-EVs as compared to S-EVs were also enriched in L-EVs in our dataset (Figure 5C, D). Interestingly, mitochondrial proteins such as TOMM20, TOMM22, MICOS complex subunits [IMMT (mitofilin) and CHCHD3], ATP synthase subunits



FIGURE 3 | The proteomes of EV subtypes are associated with different GO terms for cellular compartments. (A–D) Database for Annotation, Visualisation and Integrated Discovery (DAVID) was used to determine the enriched cellular compartments associated with proteins uniquely enriched in the four different EV subpopulations in Figure 2N. The 20 most enriched terms (based on *p* value) for each EV subtype are displayed. Next, all significant GO terms for each subpopulation were analysed with Revigo to identify networks. The largest network for each EV subtype is displayed with Cytoscape. Lastly, the presence of the GO terms included in the top network for each EV subtype was evaluated in the other EV subtypes. The enriched proteins were produced as described in Figure S3. EV, extracellular vesicle; GO, gene ontology; HD, high density; LD, low density; L-EVs, large extracellular vesicles; S-EVs, small extracellular vesicles.



FIGURE 4 | The expression of MISEV guideline proteins in the four EV subpopulations. (A–E) In the MISEV guidelines [17, 32], five categories of proteins are recommended to be evaluated in EV isolates. We have analysed all proteins in our dataset that belong to these five categories. (A) Category 1 – membrane proteins associated with the plasma membrane (PM)/endosomes. (B) Category 2 – cytosolic proteins in EVs. (C) Category 3 – major components of non-EV coisolated structures. (D) Category 4 – proteins associated with intracellular compartments other than PM/endosomes. (E) Category 5 – secreted proteins recovered with EVs. EV, extracellular vesicle; MISEV, Minimal Information for Studies of Extracellular Vesicles.

(ATP5s) were enriched in L-EVs LD in THP-1. In HMC-1 cells, several of these proteins were likewise enriched in L-EVs LD, whereas others displayed enrichment in both L-EVs LD and L-EVs HD. On the other hand, kinesins (KIFs) and cytokinesis-associated proteins such as PRC1, CIT, ANLN, PLK1, CEP55 and RACGAP1 were enriched in L-EVs HD for both cell lines. This shows that we could further separate some of the markers that have previously been suggested to be enriched in L-EVs or S-EVs to also be enriched in EVs at certain densities.

Lastly, to further determine the expression of common EV proteins in our data set, we next constructed a list of the Top 100 proteins listed at EVpedia and Vesiclepedia (Figure 6A, B). This analysis showed that proteins such as ADAM10, CD63, CD81, PDCD6IP (ALIX), TSG101, and 14-3-3 proteins (YWHAs) and EZR (Ezrin) were, as mentioned before, enriched in S-EVs LD in THP-1 (Figure 6A, Cluster 5), while proteins such as GAPDH, APOE and chaperonin-containing TCP-1 complex proteins (CCTs) were enriched in S-EVs HD in THP-1 (Figure 6A,



FIGURE 5 | Presence of previously suggested markers for L-EVs and S-EVs in EV subpopulations from immune cells. Seven studies that have used mass spectrometry to compare the proteome of L-EVs and S-EVs were used to generate two lists, one with proteins enriched in S-EVs and one with proteins enriched in L-EVs [11, 18–23]. (A, B) After removing duplicates, the S-EV list contained 58 proteins. A multi-group (ANOVA) comparison was performed in Qlucore and showed that 18 and 28 of these proteins were differentially expressed in EVs from THP-1 (p value = 0.001, q value = 0.0006453) (A) and HMC-1 (p value = 0.001, q value = 0.0012622) (B), respectively. (C, D) After removing duplicates, the L-EV list contained 129 proteins. A multi-group (ANOVA) comparison was performed in Qlucore and showed that 81 and 52 of these proteins were differentially expressed in EVs from THP-1 (p value = 0.001, q value = 0.001202) (C) and HMC-1 (p value = 0.001, q value = 0.0018211) (D), respectively. EV, extracellular vesicle; HMC-1, human mast cells; L-EVs, large extracellular vesicles; S-EVs, small extracellular vesicles; THP-1, human monocytes.



FIGURE 6 | Presence of EV markers from EV database in EV subpopulations from immune cells. The top 100 proteins identified in EVs from two online EV databases—EVpedia and VesiclePedia—were downloaded [33, 34]. After duplicates were removed, the list contained 120 proteins. (A, B) A multi-group (ANOVA) comparison was performed in Qlucore and showed that 86 and 56 of these proteins were differentially expressed in EVs from THP-1 (p value = 0.001, q value = 0.0010117) (A) and HMC-1 (p value = 0.001, q value = 0.001805) (B), respectively. EV, extracellular vesicle; HMC-1, human mast cells; THP-1, human monocytes.

Cluster 7). For HMC-1, these proteins were enriched in both S-EV subpopulations (Figure 6B, Cluster 1). SDCBP (Syntenin-1) was, as mentioned before, enriched in both S-EVs LD and HD in both cell lines (Figure 6A, Cluster 6, Figure 6B, Cluster 1). Annexins (ANXAs), Rab proteins (RABs) and flotillin-2 were enriched in both S-EVs LD and L-EVs LD in THP-1 (Figure 6A, Clusters 1 and 3), while they were not significantly different in HMC-1, suggesting that these proteins are equally expressed in L-EVs and S-EVs. Together, these data demonstrate that L-EVs LD are enriched in proteins associated with the mitochondrion, such as TIMMs/TOMMs, MICOS complex subunits and ATP synthase subunits, while L-EVs HD are enriched in KIFs and proteins associated with cytokinesis and microtubule (Figures 3–6 and summarised in Figure 7). Furthermore, S-EVs LD were enriched in proteins associated with the PM and the endosomal pathway, such as tetraspanins, ADAM10, proteins from the ESCRT machinery and 14-3-3s, while S-EVs HD were enriched in tubulins, histones, complement factors and CCT complex proteins. Additionally, some proteins were enriched in two or more EV subtypes, such as flotillins, which were similarly expressed in small and L-EVs, SDCBP being enriched in both S-EV subtypes, and RABs, annexins, some integrins and heteromeric G proteins that were enriched in both LD subtypes (Figure 7).



FIGURE 7 | Proteins enriched in subpopulations of EVs. Schematic illustration showing the proteins enriched in the four subpopulations of EVs as determined by quantitative proteomics. Proteins enriched in L-EVs LD, L-EVs HD, S-EVs LD and S-EVs HD are shown in light green, dark green, light red and dark red boxes, respectively. Proteins in the grey area are enriched in two or more subpopulations. AP, adaptor protein complex subunits; APO, apolipoproteins; CCT, chaperonin containing TCP-1 proteins; COG, conserved oligomeric Golgi complex subunits; COP, Coatomer subunits; CORVET, class C core endosomal vacuole tethering; EARP, endosome-associated recycling protein; ESCRT, endosomal sorting complexes required for transport; EV, extracellular vesicle; GARP, Golgi-associated retrograde protein; GNAs, Guanine nucleotide-binding proteins; HD, high density; HOPS, homotypic fusion and vacuole protein sorting; HSP, heat shock proteins; ITG, integrins; KIF, kinesin-like proteins; LD, low density; L-EVs, large extracellular vesicles; MICOS, mitochondrial contact site and cristae organising system; RAB, RAB G-proteins; S-EVs, small extracellular vesicles; SNX, sortin-nexins; TBC1D, TBC1 domain family; TIMM, translocase of the inner membrane of the mitochondria; TOMM, translocase of the outer membrane of the mitochondria; TRAPPC, trafficking protein particle complex subunits; TSPANs, tetraspanins; VDAC, voltage-dependent anion channels. Image was created by BioRender.com with permission.

3.4 | ADAM10 Is Expressed on Tetraspanins$^+$ EVs

As we observed that CD9, CD63, CD81 and ADAM10 were all enriched in S-EVs (Figures 4–6), and it has previously been shown that ADAM10 is associated with tetraspanins on the cell membrane and that the tetraspanins can regulate ADAM10 activity and its substrate cleavage [35–37], we decided to analyse all tetraspanins and ADAMs/ADAMTSs in more detail in our dataset. All tetraspanins were enriched in S-EVs with a further enrichment in S-EVs LD in THP-1, except for CD151, which was enriched in L-EVs LD for both cell lines (Figure 8A, B). For the ADAMs/ADAMTSs, ADAM10 was enriched in S-EVs LD, while ADAM17 was enriched in both S-EVs LD and L-EVs LD (Figure 8C, D). Additionally, in THP-1, the ADAMTSs were mostly enriched in S-EVs HD (Figure 8C, D). As proteomics is a bulk analysis, we next set out to determine if ADAM10 and tetraspanins are coexpressed on the same EVs. To do so, we analysed S-EVs from the HMC-1 with a flow nanoAnalyzer. As we have observed in previous flow nanoAnalyzer experiments that iodixanol can interfere with the flow nanoAnalyzer measurements, it was not feasible to analyse the S-EVs LD, instead, we used crude S-EVs to investigate the presence of CD9, CD63, CD81 and ADAM10 on their surface. It was shown that the majority of ADAM10 is expressed on EVs that also express CD9, CD63 and/or CD81 in S-EVs (Figure 8E). Importantly, Triton-X treatment disrupted the majority of the ADAM10$^+$ and tetraspanins$^+$ EVs, suggesting they are true EVs (Figure S6). All relevant controls for the flow nanoAnalyzer can be found in Figures S6–S8.

3.5 | The Lipidomes of the Four EV Subpopulations Are Altered

Next, we sought to determine the lipid composition of the EV subtypes. We performed mass spectrometry to determine the presence of 107 lipids in the four subpopulations of EVs, all analysed in biological quadruplicates for each cell line. Overall, the four media-only blanks contained low levels of lipids. Importantly, they contained substantially less than the



FIGURE 8 | ADAM10 is present on tetraspanins expressing EVs. (A–D) A multi-group (ANOVA) comparison was performed in Qlucore with a focus on the tetraspanins (A, B) and ADAMs and ADAMTSs (C, D). (E) NanoFCM was used to determine the coexpression of ADAM10 and tetraspanins on single S-EVs. S-EVs from HMC-1 cells were stained for ADAM10 and an anti-tetraspanins mix containing antibodies for CD63, CD9 and CD81. EV, extracellular vesicle; HMC-1, human mast cells; S-EV, small extracellular vesicle.

corresponding samples, with a median contribution of 0.6% from the media-only blanks to the lipids in the samples. One exception was LPC(18:2)_B, which was high in one of the media-only blanks. Interpretation of this lipid should therefore be made with caution.

To visualise the relationship between the different types of isolated EVs, a PCA was performed for each cell line, including all lipids. The samples were well grouped based on EV type and Component 1, representing over 60% of the variability in THP-1, distinguished L-EVs and S-EVs (Figure 9A, B). Furthermore, Components 2 and 3 distinguished the LD and HD fractions; however, this was more evident in the HMC-1-derived EVs as compared to the THP-1-derived EVs. A similar pattern was observed when all samples from both cell lines were analysed in the same PCA plot, although the samples separated based on cell type (Figure 9C).

Firstly, we analysed the lipids at the group level for each lipid type. Notably, significant differences were observed between the two cell lines. Although sphingomyelins (SM) and ceramides (Cer) were more common in HMC-1 EVs as compared to THP-1 EVs, phosphatidylcholine (PC), phosphatidylinositols (PIs), glucosylceramide (GlcCer) and phosphatidylglycerol (PG) were more abundant in THP-1 EVs as compared to HMC-1 EVs (Figure 9D–M). Indeed, SM was the most abundant lipid in HMC-1 EVs, whereas PC was the most abundant lipid in THP-1 EVs. Importantly, there were differences between the EV



FIGURE 9 | Lipidomic analysis of a subpopulation of EVs from immune cells. Mass spectrometry was used to determine the differences between 107 lipids in the EV subpopulations. Four biological replicates (10 µL EVs/sample) were used from both cell lines. (A–C) Principal component analysis illustrating the relationship between the subpopulations derived from HMC-1 (A), THP-1 (B) and both cell lines combined (C). (D–M) The % for each lipid class of the total lipids is illustrated. EV, extracellular vesicle; HMC-1, human mast cells, THP-1, human monocytes.

subpopulations; most prominent was the lower abundance of phosphatidylethanolamine (PE) in L-EVs LD compared to all three other EV subpopulations (Figure 9D, E, H). In the HMC-1 L-EVs LD, this was mainly compensated by an increase in SM, PI and LPC, while in THP-1 L-EVs LD, it was compensated by an increase in PC, PI and PG (Figure 9D–M). Furthermore, Cer, PI and LPC were more abundant in L-EVs compared to S-EVs, while SM and GlcCer were more enriched in S-EVs at least in the THP-1 EVs (Figure 9D–M).

Secondly, we focused on an analysis of individual lipids. We identified the 10 most abundant lipids in each EV subtype. In each sample, these 10 lipids represented approximately 70% of all the lipids (Figure 10A). In the HMC-1 cell line, one of the largest differences was for PE(O-2:0_18:1), a plasmanyl and PE(O-2:0_18:2), which were less common in L-EVs LD. Additionally, Cer(d18:1/22:0) and Cer(d18:1/16:0) were less common in S-EVs compared to L-EVs. In the THP-1 cell line, there was a large difference in PC(16:0/16:0), also called (DPPC), that was much less abundant in L-EVs as compared to S-EVs. Additionally, PE(O-2:0_18:2) was also less abundant in L-EVs LD, similar to that for HMC-1.

Focusing on lipids that were commonly altered in both cell lines, analysis of individual lipids also demonstrated that Cer(d18:1/22:5), Cer(d18:1/18:0), Cer(d18:1/16:0), Cer(d18:1/22:3) and Cer(d18:1/14:0) were enriched in both L-EV subpopulations compared to S-EVs (Figure 10B, Cluster 4 and Figure 10C, Cluster 3). Conversely, SM(36:2;O2) was enriched in S-EVs HD/S-EVs compared to L-EVs (Figure 10B, Cluster 1 and Figure 10C, Cluster 1), and PC(18:0_18:1) and PC(18:1_20:4) were enriched in S-EVs HD compared to all three other subpopulations (Figure 10B, Cluster 1 and Figure 10C, Cluster 2). Meanwhile, several of the other PCs were enriched in other subpopulations.



FIGURE 10 | Analysis of individual lipids. (A) The Top 10 most abundant lipids in each EV subtype and their positions in the other EV subtypes. (B, C) A multi-group (ANOVA) comparison was performed in Qlucore for lipids in EVs from HMC-1 (B) and THP-1 (C). EV, extracellular vesicle; HMC-1, human mast cells; THP-1, human monocytes.

Lastly, LPC(18:1)_B, LPC(16:1)_B, PC(16:1_16:1), PC(14:0_18:2), PC(16:1_18:1), PC(14:1_16:0), PC(16:1_18:1), PI(16:0_18:1) and PI(18:0_18:1) were enriched in L-EVs LD/L-EVs (Figure 10B, Cluster 3 and Figure 10C, Cluster 3).

Together, this suggests that even though the most abundant lipids are similar in the different EV subtypes, there are differences in individual lipids and for some of the lipid classes, such as PE and Cer.

4 | Discussion

Few studies have compared the proteome and lipidome of multiple EV subtypes. Most studies focus on a single EV subtype, limiting the knowledge of which proteins and lipids are common and which are enriched in certain EV subpopulations. We present here an in-depth analysis of the proteome and lipidome of four subpopulations of EVs from immune cells to address this knowledge gap. The proteomes of the four EV subtypes were well separated and had distinct protein profiles. Mitochondrial and cytoskeleton proteins were enriched in L-EVs LD and L-EVs HD, respectively. Tetraspanins, ESCRT machinery proteins and 14-3-3 proteins were enriched in S-EVs LD, while histones, complement factors and CCT proteins were enriched in S-EVs HD. Proteins such as flotillins, RABs, heat shock proteins, guanine nucleotide-binding proteins (GNAs) and integrins were enriched in two or more EV subtypes, while proteins involved in the transport of proteins and membranes between organelles and the PM were similarly expressed in all four EV subtypes. The lipidome was relatively similar for the EV subpopulations, with lipids such as SM(34:1;O2) and PC(16:0_18:1) being the most abundant lipids in several of the EV subtypes. However, PE was substantially lower in L-EVs LD as compared to all the other subpopulations, and ceramides were more abundant in L-EVs as compared to S-EVs.

We identified several groups of proteins, such as APs, COGs, TRAPPCs, SNXs, TPC1Ds, COPs and VPSs, that belong to different tethering complexes, which were all equally expressed in all four subtypes of EVs. Interestingly, several of these are involved in membrane and protein trafficking by transport vesicles between different organelles and between the PM and organelles. When proteins and lipids are transported from the PM and the *trans*-Golgi network (TGN) to the endosome in clathrin-coated vesicles, APs recruit clathrin to the membrane. AP-1 complex is participating in the process at the TGN, while AP-2 is participating at the PM [38]. Other than clathrin, transport vesicles can be coated with COPs, such as COPI or COPII. While COPI vesicles are trafficking from the Golgi to the ER and within the Golgi, the COPII vesicles are trafficking in the opposite direction from the ER to the Golgi [13]. Tethering factors participate in the initial contact between the transport vesicles and the target membrane. Examples of tethering complexes are TRAPPCs, COGs, CORVETs, HOPSs, EARPs and GARPs that later bind to RABs and SNAREs to dock the transport vesicles to the target membrane [14]. While COGs are involved in intra-Golgi retrograde trafficking mediated by COPI vesicles, TRAPPCs are involved in transport between ER and Golgi and endosome and Golgi via both COPI and COPII vesicles. CORVET, HOPS and EARP are involved in the fusion of early endosomes, late endosome, and recycling endosomes, respectively, while GARP is involved in recycling to the TGN. The fact that these proteins were similarly expressed across all EV subtypes and could therefore be considered part of a core EV proteome suggests that intracellular membrane-trafficking machinery may be important for multiple EV types.

We also identified several proteins that were enriched in one or several EV subtypes. The proteins enriched in L-EVs LD were associated with mitochondrion and ER. Specifically, proteins such as TIMM/TOMM, MICOS and ATP-synthase proteins were significantly enriched in L-EV fractions, but commonly with a higher enrichment in the L-EVs LD. This validates previous studies by us and others that L-EVs from both cell lines and clinical samples are enriched in mitochondrial proteins such as mitofilin (IMMT), ATP5O, ATP5F1B and ATP5F1A [11, 19, 21–24, 39–41]. Additionally, there are papers suggesting that L-EVs can transport whole mitochondria [42, 43]. However, there are also studies showing that S-EVs contain, for example, mitochondrial DNA or mitochondrial proteins [12, 42, 44, 45]. Furthermore, it has been suggested that mitochondria protein-containing vesicles, mitovesicles, are a novel population of EVs, distinct from both S-EVs and L-EVs, such as exosomes and microvesicles [46]. Lastly, it has also been demonstrated that the amount of EVs containing mitochondrial proteins is altered in Down syndrome, asthma and cancer [45–47]. Puhm et al. also showed that stimulating THP-1 cells with LPS, the same cells that we used here, increased TOMM22 in L-EVs, suggesting that stress can enrich the mitochondrial content in L-EVs [48]. Together, these findings suggest that there is an interaction or overlap between processes in the mitochondrion and the biogenesis of certain subpopulations of EVs and that this may be altered in pathophysiological conditions.

On the other hand, proteins enriched in L-EVs HD were associated with the cytosol, the cytoskeleton and the kinesin complex. Specifically, proteins associated with cytokinesis, such as microtubules- and central spindle complex-associated proteins, including KIFs, PRC1 and RACGAP1, were enriched. During cell division, RACGAP1 interacts with KIF23 and PRC1 to form and stabilise the central spindle, and it has been shown that RACGAP1 is overexpressed in several cancers [49]. About half of the proteins belonging to the kinesin superfamily proteins (KIFs) were quantified in our proteomics analysis, and the majority of the quantified KIFs showed significant enrichment in L-EVs HD. The enrichment observed in L-EVs HD isolated in this study validates previous studies published by us and others, where it was shown that KIFs and RACGAP1 are enriched in L-EVs [11, 22, 24, 50, 51] and further enriched in L-EVs HD [20]. Rai and coworkers suggested that the EVs containing the midbody remnants are a distinct EV subpopulation from exosomes (S-EVs) and microvesicles (L-EVs), and our data may support this, as these proteins were uniquely upregulated in L-EVs HD in both cell lines.

Additionally, some protein groups were enriched in both L-EVs LD and HD, such as heat shock proteins and voltage-dependent anion channels (VDAC). Heat shock proteins are involved in the folding, unfolding and stabilisation of proteins and thereby ensure correct folding, but they also have a multitude of other functions. In our previous study, we found that the majority of heat shock proteins were enriched in L-EVs [11], which others have also observed [19, 22, 23, 52, 53]. We could confirm it here and further show that there was little difference between the L-EVs LD and HD. However, this time we also included the type two chaperonins 'chaperonin containing TCP-1' (CCT) proteins, which fold about 10% of all proteins with a focus on actin and tubulin, but also proteins essential for cancer development [54]. Interestingly, these CCTs tended to be enriched in S-EVs instead, with the highest abundance in S-EVs HD, showing a distinct distribution compared to the other heat shock proteins. In previous studies, CCTs have been identified as both enriched

in S-EVs [53] and L-EVs [22, 55]. Interestingly, Rojas-Gómez et al. recently suggested that CCTs control EV production by affecting the number and size of lipid droplets, and by affecting the kinesin dynamics, inter-organelle contacts and movement. Specifically, cells treated with siRNA to reduce the CCTs expression released more S-EVs, which was suggested to be an effect of the redirection of the endolysosomal pathway to multivesicular body biogenesis and EV release [56].

Additionally, some protein groups were enriched in both L-EVs HD and S-EVs HD, such as tubulins. Tubulins have previously been shown to be enriched in both L-EVs [22, 53] and S-EVs HD [57], demonstrating their presence in both L-EVs and S-EVs. Our data clearly showed that when separated based on density, the tubulins would end up in the HD fraction for both L-EVs and S-EVs.

Besides the tubulins and CCTs mentioned above, S-EVs HD were also enriched in histones, complement proteins, apolipoproteins and collagens compared to the other EV subpopulations. These proteins are commonly considered to be a contamination suggested to be copelleting with S-EVs during ultracentrifugation. However, the S-EVs HD floated up from the bottom, where the crude EVs were loaded to the collection fraction of the HD EVs (above 32%). This means that histones, complement proteins, apolipoproteins and collagens must have been attached to a lipid structure to move up to this density, as free protein would not float. In recent years, the investigations of a protein corona surrounding EVs have increased. The EV protein corona is a group of proteins that are attached to the vesicle surface after the vesicle is released. The reason for their binding can be due to, but not limited to, electrostatic interactions, proximity, protein aggregation and receptor/ligand binding. Proteins that are adsorbed to EVs, creating the corona, are, for example, albumin, apolipoprotein, complement factors, cytokines and fibrinogen [58, 59]. We currently do not know if these proteins are attached as a corona or loaded inside the S-EV HD. If we speculate that these proteins are derived from a corona, we currently did not determine whether it is a biological feature, hence, S-EVs attract more proteins than L-EVs, or if it is a technical issue, such as that more proteins are forced to attach to S-EVs due to the higher g forces needed to pellet crude S-EVs as compared to L-EVs. However, it has been suggested that glycoproteins on EVs can bind some of the corona proteins [58], and interestingly, glypican-1, glypican-2, syndican-2 and syndecan-4 are enriched in S-EVs in our dataset. Additionally, we also do not know if the HD and LD S-EVs are two distinct S-EV subpopulations and therefore attract these proteins differently, or if the EVs are the same, but due to more protein corona one subtype ends up at a higher density. Future studies about protein corona versus coisolation of contaminants with different EV subtypes are needed. Interestingly, a recent study showed that histones were associated with the membrane of tetraspanin-positive S-EVs [60]. Furthermore, they observed that histones were also present in CD63-positive intraluminal vesicles in multivesicular bodies, showing that the histones can be released associated with S-EVs and hence, not attached as a corona after the secretion.

Proteins enriched in S-EVs LD were tetraspanins, ESCRT complex proteins, 14-3-3 and ADAM10. As S-EVs are the most studied EV subtype, they are commonly known to be present in S-EVs. We and others have previously also shown that they are enriched in S-EVs as compared to L-EVs and/or further enriched in S-EVs LD as compared to S-EVs HD [11, 19, 21–24, 50, 52, 53, 57, 61–64] from both cell lines and clinical samples. ADAM10 belongs to a family of transmembrane proteins that are involved in ectodomain shedding and cell adhesion. Interestingly, it has been shown that ADAM10 is associated with tetraspanins on cells and that some tetraspanins have been shown to regulate the ADAM10 surface expression levels and its activation for its cleavage of several substrates [35–37]. Furthermore, it has been shown that EVs contain active ADAM10 that can cleave its substrate [65]. We show here that ADAM10 is mainly expressed on EVs that also express tetraspanins. Although we could not analyse the S-EV LD fraction for technical reasons, but rather analysed the crude S-EVs, this suggests a close relationship between ADAMs and tetraspanins that may be of interest for future EV studies to determine in more detail.

Lastly, we also identified some protein groups that were enriched in two or more EV subpopulations. Although flotillins were enriched in all subpopulations, GNA proteins, integrins and annexins were enriched in both S-EVs LD and L-EVs LD, and Syntenin-1 and syndecans were enriched in both S-EVs LD and S-EVs HD. As some studies have previously suggested that annexins are enriched in L-EVs while others have suggested that they are enriched in S-EVs [21, 52, 53, 62, 66], these proteins are most likely not good markers to distinguish EV subpopulations as their expression may be different depending on cell source. Most other studies have suggested that integrins are enriched in S-EVs [23, 50, 61, 66, 67], and we observe that for some of the integrins, while others are enriched in both S-EVs LD and L-EVs LD, which suggests that their expressions are also cell source dependent. Syntenin-1 (SDCBP) has mainly been shown previously to be enriched in S-EVs by us and others [11, 19, 22, 30, 57, 61, 62, 68] and has also been suggested to be part of the biogenesis of exosomes together with syndecans and ALIX (PDCD6IP) [69]. We report here that we observed similar enrichment in S-EVs HD and LD for syntenin-1 and syndecans, which may suggest that both these EV types have similar biogenesis.

Next, we also determined the lipid content of the different subpopulations of EVs. In contrast to the proteomic analysis, which is unbiased, the lipidomic analysis is targeted, with a list of 107 lipids being included in our analysis. Cholesterol has been suggested to make up over 40% of EV lipids [70, 71]. However, as cholesterol was not included in our analysis, this should be considered when comparing percentages between studies. It is important to note that lipids are inherently present in the culture medium, especially if FBS is used in the medium, and care must be taken to account for potential lipid contaminants that may coisolate with EV preparations.

Overall, the lipid content of S-EVs and L-EVs was quite similar, which confirms previous observations by others in EVs from seminal plasma and cell lines [40, 68]. Haraszti et al., for example, observed that the lipid content of L-EVs and S-EVs was more similar than the protein content. However, when comparing EVs from three different cell lines, they noted differences between the cell lines [40]. Our findings were consistent with this observation. Durcin et al. also suggested similarity in the lipid profile of L-EVs and S-EVs except for cholesterol content and externalised

PS, two parameters we did not evaluate in our study [53]. Zhang et al. demonstrated that S-EVs of different sizes had similar lipid cargo; however, exomers had distinct lipids [72]. Also, Zhang and coworkers showed that the lipid content in EVs was cell-type specific. However, we and others have detected differences in sphingolipids and phospholipids. For example, others have observed more Cer in L-EVs compared to S-EVs, while more SM was observed in S-EVs compared to L-EVs [73–76]. This could be verified in our study as we identified more Cer in L-EVs in both cell lines and more SM in S-EVs in THP-1. In previous studies that have compared the lipids of S-EVs with the lipids in the membrane of EV-producing cells, SM and Cer are two of the lipid groups that are usually enriched in the EV membrane compared to the cell membrane [77]. Cer is known to increase membrane order and rigidity, as well as negative curvature, and have been suggested to be important for the formation of intraluminal vesicles in multivesicular bodies [78]. A difference in the ratio of SM and Cer in the EV membrane can therefore potentially influence vesicle curvature, rigidity and membrane stability.

The most profound difference in our dataset was that PE was lower in L-EVs LD compared to all three of the other subpopulations. Tacconi et al. focused their analysis on how the lipid cargo of S-EVs and L-EVs from macrophages was altered in high glucose environments, but their data suggest that L-EVs have less PE [74]. Additionally, S-EVs from platelets have been shown to have more PE than L-EVs [75]. PE is the second most abundant phospholipid, and it preferentially localises to the inner leaflet of the PM in cells [79]. In previous studies that have compared the lipids of S-EVs with the lipids in the membrane of EV-producing cells, PE is one of the lipids that has similar expression in the EV and cell membrane [77]. Furthermore, PE contributes to negative curvature and is involved in membrane fusion/fission, membrane budding and mitochondrial cristae. Additionally, PE is required for GPI-anchored protein maturation [80]. A difference in PE abundance in the EV membrane can therefore potentially influence vesicle curvature, rigidity or membrane stability.

In conclusion, our study shows that the proteome and lipidome of large and S-EV subpopulations of different densities are substantially different. However, this was more prominent for the proteome than for the lipidome. Importantly, we cannot exclude that additional EV subtypes exist within these four subpopulations, and future studies will have to dissect this further. Here, we suggest proteins and lipids that are enriched in one or more of our EV subpopulations, but have also identified molecules that are similarly expressed in all EV subtypes. Detailed characterisation of the protein and lipid cargo within EV subpopulations is essential for advancing EV research across a range of biomedical applications. Defining specific molecular markers can enhance the evaluation of EV isolation and purification strategies, particularly when a single EV subpopulation is the primary focus. Although we do not provide any functional or mechanistic data here, we suggest that identifying EV subtype markers can also provide deeper insights into EV biology, support the discovery of clinically relevant biomarkers, and EV-based therapeutics. As it has been shown that subpopulations of EVs have different functions [81], they may not all contribute equally in a disease; therefore, studying a mixture of EV subtypes might mask important functions or potential EV-associated biomarkers. Defining specific molecular markers can enhance the possibility to identify these features.

Author Contributions

Anna Lischnig: methodology, formal analysis, investigation, writing – original draft, visualisation. **Nasibeh Karimi**: methodology, investigation, writing – review and editing. **Per Larsson**: methodology, formal analysis, investigation, writing – review and editing. **Karin Ekström**: methodology, formal analysis, investigation, writing – review and editing. **Rossella Crescitelli**: methodology, investigation, writing – review and editing. **Anna-Carin Olin**: investigation, writing – review and editing. **Cecilia Lässer**: conceptualisation, methodology, formal analysis, investigation, writing – original draft, visualisation, supervision, project administration, funding acquisition.

Acknowledgements

We thank the Centre for Cellular Imaging at the University of Gothenburg and the National Microscopy Infrastructure (VR-RFI 2016-00968) for microscopy support. We also wish to acknowledge Annika Thorsell and Elham Rekabdar at the Proteomics Core Facility at Sahlgrenska Academy, University of Gothenburg, for performing the LC-tandem MS analysis. The Proteomics Core Facility, Sahlgrenska academy, Gothenburg University, is supported with financial support from SciLifeLab and BioMS.

Funding

This study was funded by the Swedish Heart-Lung Foundation (20210166), the Emil and Wera Cornell Foundation, the Wilhelm and Martina Lundgrens Science Foundation (2020-3547) and ALF agreement Västra Götaland, Sweden (ALFGBG-1006651). Open Access funding was provided by the University of Gothenburg. This research received funding from the Erasmus+ Programme of the European Union. We also thank the Herman Krefting Foundation for Asthma and Allergy Research for funding the Krefting Research Centre at the University of Gothenburg. Rossella Crescitelli was supported by Vetenskapsrådet Etableringsbidrag (Starting Grant from the Swedish Research Council) (Grant # 2023-02239), Assar Gabrielsson's Foundation (Grant # FB23-01), the Serena Ehrenström foundation, the Ann-Lisa och Bror Björnssons Foundation, Wilhelm och Martina Lundgrens Vetenskapsfond (Grant # 2023-SA-4142) and Magnus Bergvalls Stiftelse (Grant # 2024-1009).

Conflicts of Interest

C.L. and R. C. have developed EV-associated patents for putative clinical utilisation. C. L. and R.C. have equity in Exocure Sweden AB, a startup developing EVs for therapeutic purposes. The remaining authors have no competing interests.

Data Availability Statement

The MS proteomics data have been deposited to the ProteomeX-change Consortium via the PRIDE partner repository with the dataset identifier PXD063334 [82, 83]. We have submitted all relevant data from our experiments to the EV-TRACK knowledgebase (EV-TRACK ID:EV250057 [84].

References

1. Y. Couch, E. I. Buzàs, D. Di Vizio, et al., "A Brief History of Nearly EV-Erything—The Rise and Rise of Extracellular Vesicles," *Journal of Extracellular Vesicles* 10, no. 14 (2021): 12144, https://doi.org/10.1002/jev2.12144.

2. A. G. Yates, R. C. Pink, U. Erdbrügger, et al., "In Sickness and in Health: The Functional Role of Extracellular Vesicles in Physiology and Pathology

In Vivo," *Journal of Extracellular Vesicles* 11, no. 1 (2022): 12151, https://doi.org/10.1002/jev2.12151.

3. A. G. Yates, R. C. Pink, U. Erdbrügger, et al., "In Sickness and in Health: The Functional Role of Extracellular Vesicles in Physiology and Pathology In Vivo," *Journal of Extracellular Vesicles* 11, no. 1 (2022): 12190, https://doi.org/10.1002/jev2.12190.

4. C. Lasser, S. C. Jang, and J. Lotvall, "Subpopulations of Extracellular Vesicles and Their Therapeutic Potential," *Molecular Aspects of Medicine* 60 (2018): 1–14, https://doi.org/10.1016/j.mam.2018.02.002.

5. O. P. B. Wiklander, M. A. Brennan, J. Lotvall, X. O. Breakefield, and S. El Andaloussi, "Advances in Therapeutic Applications of Extracellular Vesicles," *Science Translational Medicine* 11, no. 492 (2019): aav8521, https://doi.org/10.1126/scitranslmed.aav8521.

6. W. Phillips, E. Willms, and A. F. Hill, "Understanding Extracellular Vesicle and Nanoparticle Heterogeneity: Novel Methods and Considerations," *Proteomics* 21, no. 13-14 (2021): 2000118, https://doi.org/10.1002/pmic.202000118.

7. A. Z. Fernandis and M. R. Wenk, "Membrane Lipids as Signaling Molecules," *Current Opinion in Lipidology* 18, no. 2 (2007): 121–128, https://doi.org/10.1097/MOL.0b013e328082e4d5.

8. J. H. Butterfield, D. Weiler, G. Dewald, and G. J. Gleich, "Establishment of an Immature Mast Cell Line From a Patient With Mast Cell Leukemia," *Leukemia Research* 12, no. 4 (1988): 345–355, https://doi.org/10.1016/0145-2126(88)90050-1.

9. G. Nilsson, T. Blom, M. Kusche-Gullberg, et al., "Phenotypic Characterization of the Human Mast-Cell Line HMC-1," *Scandinavian Journal of Immunology* 39, no. 5 (1994): 489–498, https://doi.org/10.1111/j.1365-3083.1994.tb03404.x.

10. S. Tsuchiya, M. Yamabe, Y. Yamaguchi, Y. Kobayashi, T. Konno, and K. Tada, "Establishment and Characterization of a human Acute Monocytic Leukemia Cell Line (THP-1)," *International Journal of Cancer* 26, no. 2 (1980): 171–176, https://doi.org/10.1002/ijc.2910260208.

11. A. Lischnig, M. Bergqvist, T. Ochiya, and C. Lasser, "Quantitative Proteomics Identifies Proteins Enriched in Large and Small Extracellular Vesicles," *Molecular & Cellular Proteomics* 21, no. 9 (2022): 100273, https://doi.org/10.1016/j.mcpro.2022.100273.

12. E. Lázaro-Ibáñez, C. Lässer, G. V. Shelke, et al., "DNA Analysis of Low- and High-Density Fractions Defines Heterogeneous Subpopulations of Small Extracellular Vesicles Based on Their DNA Cargo and Topology," *Journal of Extracellular Vesicles* 8, no. 1 (2019): 1656993, https://doi.org/10.1080/20013078.2019.1656993.

13. T. Kirchhausen, "Three Ways to Make a Vesicle," *Nature Reviews Molecular Cell Biology* 1, no. 3 (2000): 187–198, https://doi.org/10.1038/35043117.

14. M. Sacher, N. Shahrzad, H. Kamel, and M. P. Milev, "TRAPPopathies: An Emerging Set of Disorders Linked to Variations in the Genes Encoding Transport Protein Particle (TRAPP)-Associated Proteins," *Traffic (Copenhagen, Denmark)* 20, no. 1 (2019): 5–26, https://doi.org/10.1111/tra.12615.

15. F. Supek, M. Bosnjak, N. Skunca, and T. Smuc, "REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms," *PLoS ONE* 6, no. 7 (2011): 21800, https://doi.org/10.1371/journal.pone.0021800.

16. P. Shannon, A. Markiel, O. Ozier, et al., "Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks," *Genome Research* 13, no. 11 (2003): 2498–2504, https://doi.org/10.1101/gr.1239303.

17. J. A. Welsh, D. C. I. Goberdhan, L. O'Driscoll, et al., "Minimal Information for Studies of Extracellular Vesicles (MISEV2023): From Basic to Advanced Approaches," *Journal of Extracellular Vesicles* 13, no. 2 (2024): 12404, https://doi.org/10.1002/jev2.12404.

18. H. J. Lim, H. Yoon, H. Kim, et al., "Extracellular Vesicle Proteomes Shed Light on the Evolutionary, Interactive, and Functional Divergence of Their Biogenesis Mechanisms," *Frontiers in Cell and Developmental Biology* 9 (2021): 734950, https://doi.org/10.3389/fcell.2021.734950.

19. A. Rai, H. Fang, B. Claridge, R. J. Simpson, and D. W. Greening, "Proteomic Dissection of Large Extracellular Vesicle Surfaceome Unravels Interactive Surface Platform," *Journal of Extracellular Vesicles* 10, no. 13 (2021): 12164, https://doi.org/10.1002/jev2.12164.

20. A. Rai, D. W. Greening, Xu, M. Chen, W. Suwakulsiri, and R. J. Simpson, "Secreted Midbody Remnants Are a Class of Extracellular Vesicles Molecularly Distinct From Exosomes and Microparticles," *Communications Biology* 4, no. 1 (2021): 400, https://doi.org/10.1038/s42003-021-01882-z.

21. J. Kowal, G. Arras, M. Colombo, et al., "Proteomic Comparison Defines Novel Markers to Characterize Heterogeneous Populations of Extracellular Vesicle Subtypes," *Proceedings of the National Academy of Sciences of the United States of America* 113, no. 8 (2016): E968–E977, https://doi.org/10.1073/pnas.1521230113.

22. R. Xu, D. W. Greening, A. Rai, H. Ji, and R. J. Simpson, "Highly-Purified Exosomes and Shed Microvesicles Isolated From the Human Colon Cancer Cell Line LIM1863 by Sequential Centrifugal Ultrafiltration Are Biochemically and Functionally Distinct," Methods (San Diego, Calif.) 87 (2015): 11–25, https://doi.org/10.1016/j.ymeth.2015.04.008.

23. V. R. Minciacchi, S. You, C. Spinelli, et al., "Large Oncosomes Contain Distinct Protein Cargo and Represent a Separate Functional Class of Tumor-Derived Extracellular Vesicles," *Oncotarget* 6, no. 13 (2015): 11327–11341, https://doi.org/10.18632/oncotarget.3598.

24. V. Dozio and J. C. Sanchez, "Characterisation of Extracellular Vesicle-Subsets Derived From Brain Endothelial Cells and Analysis of Their Protein Cargo Modulation After TNF Exposure," *Journal of Extracellular Vesicles* 6, no. 1 (2017): 1302705, https://doi.org/10.1080/20013078.2017.1302705.

25. M. Bergqvist, K. S. Park, N. Karimi, L. Yu, C. Lasser, and J. Lotvall, "Extracellular Vesicle Surface Engineering With Integrins (ITGAL & ITGB2) to Specifically Target ICAM-1-Expressing Endothelial Cells," *Journal of Nanobiotechnology* 23, no. 1 (2025): 64, https://doi.org/10.1186/s12951-025-03125-3.

26. M. Bergqvist, C. Lasser, R. Crescitelli, K. S. Park, and J. Lotvall, "A Non-Centrifugation Method to Concentrate and Purify Extracellular Vesicles Using Superabsorbent Polymer Followed by Size Exclusion Chromatography," *Journal of Extracellular Vesicles* 14, no. 1 (2025): 70037, https://doi.org/10.1002/jev2.70037.

27. J. A. Welsh, E. Van Der Pol, G. J. A. Arkesteijn, et al., "MIFlowCyt-EV: A Framework for Standardized Reporting of Extracellular Vesicle Flow Cytometry Experiments," *Journal of Extracellular Vesicles* 9, no. 1 (2020): 1713526, https://doi.org/10.1080/20013078.2020.1713526.

28. J. A. Welsh, G. J. A. Arkesteijn, M. Bremer, et al., "A Compendium of Single Extracellular Vesicle Flow Cytometry," *Journal of Extracellular Vesicles* 12, no. 2 (2023): 12299, https://doi.org/10.1002/jev2.12299.

29. X. Osteikoetxea, B. Sódar, A. Németh, et al., "Differential Detergent Sensitivity of Extracellular Vesicle Subpopulations," *Organic & Biomolecular Chemistry* 13, no. 38 (2015): 9775–9782, https://doi.org/10.1039/C5OB01451D.

30. F. G. Kugeratski, K. Hodge, S. Lilla, et al., "Quantitative Proteomics Identifies the Core Proteome of Exosomes With Syntenin-1 as the Highest Abundant Protein and a Putative Universal Biomarker," *Nature Cell Biology* 23, no. 6 (2021): 631–641, https://doi.org/10.1038/s41556-021-00693-y.

31. J. Lötvall, A. F. Hill, F. Hochberg, et al., "Minimal Experimental Requirements for Definition of Extracellular Vesicles and Their Functions: A Position Statement From the International Society for Extracellular Vesicles," *Journal of Extracellular Vesicles* 3 (2014): 26913, https://doi.org/10.3402/jev.v3.26913.

32. C. Théry, K. W. Witwer, E. Aikawa, et al., "Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): A Position Statement of the International Society for Extracellular Vesicles and Update of the

MISEV2014 Guidelines," *Journal of Extracellular Vesicles* 7, no. 1 (2018): 1535750, https://doi.org/10.1080/20013078.2018.1535750.

33. D. K. Kim, B. Kang, O. H. Y. Kim, et al., "EVpedia: An Integrated Database of High-Throughput Data for Systemic Analyses of Extracellular Vesicles," *Journal of Extracellular Vesicles* 2 (2013): 20384, https://doi.org/10.3402/jev.v2i0.20384.

34. S. V. Chitti, S. Gummadi, T. Kang, et al., "Vesiclepedia 2024: An Extracellular Vesicles and Extracellular Particles Repository," *Nucleic Acids Research* 52, no. D1 (2024): D1694–D1698, https://doi.org/10.1093/nar/gkad1007.

35. C. Arduise, T. Abache, L. Li, et al., "Tetraspanins Regulate ADAM10-Mediated Cleavage of TNF-α and Epidermal Growth Factor," *Journal of Immunology* 181, no. 10 (2008): 7002–7013, https://doi.org/10.4049/jimmunol.181.10.7002.

36. M. Yanez-Mo, F. Sanchez-Madrid, and C. Cabanas, "Membrane Proteases and Tetraspanins," *Biochemical Society Transactions* 39, no. 2 (2011): 541–546, https://doi.org/10.1042/BST0390541.

37. S. Jouannet, J. Saint-Pol, L. Fernandez, et al., "TspanC8 Tetraspanins Differentially Regulate the Cleavage of ADAM10 Substrates, Notch Activation and ADAM10 Membrane Compartmentalization," *Cellular and Molecular Life Sciences: CMLS* 73, no. 9 (2016): 1895–1915, https://doi.org/10.1007/s00018-015-2111-z.

38. T. Kirchhausen, "Adaptors for Clathrin-Mediated Traffic," *Annual Review of Cell and Developmental Biology* 15 (1999): 705–732, https://doi.org/10.1146/annurev.cellbio.15.1.705.

39. L. Wu, L. Zhou, J. An, et al., "Comprehensive Profiling of Extracellular Vesicles in Uveitis and Scleritis Enables Biomarker Discovery and Mechanism Exploration," *Journal of Translational Medicine* 21, no. 1 (2023): 388, https://doi.org/10.1186/s12967-023-04228-x.

40. R. A. Haraszti, M. C. Didiot, E. Sapp, et al., "High-Resolution Proteomic and Lipidomic Analysis of Exosomes and Microvesicles From Different Cell Sources," *Journal of Extracellular Vesicles* 5 (2016): 32570, https://doi.org/10.3402/jev.v5.32570.

41. T. Ahmadzada, A. Vijayan, F. Vafaee, et al., "Small and Large Extracellular Vesicles Derived From Pleural Mesothelioma Cell Lines Offer Biomarker Potential," *Cancers (Basel)* 15, no. 8 (2023): 2364, https://doi.org/10.3390/cancers15082364.

42. D. G. Phinney, M. Di Giuseppe, J. Njah, et al., "Mesenchymal Stem Cells Use Extracellular Vesicles to Outsource Mitophagy and Shuttle microRNAs," *Nature Communications* 6 (2015): 8472, https://doi.org/10.1038/ncomms9472.

43. A. D'Souza, A. Burch, K. M. Dave, et al., "Microvesicles Transfer Mitochondria and Increase Mitochondrial Function in Brain Endothelial Cells," *Journal of Controlled Release* 338 (2021): 505–526, https://doi.org/10.1016/j.jconrel.2021.08.038.

44. N. Rabas, S. Palmer, L. Mitchell, et al., "PINK1 Drives Production of mtDNA-Containing Extracellular Vesicles to Promote Invasiveness," *The Journal of Cell Biology* 220, no. 12 (2021): 202006049, https://doi.org/10.1083/jcb.202006049.

45. K. P. Hough, J. L. Trevor, J. G. Strenkowski, et al., "Exosomal Transfer of Mitochondria From Airway Myeloid-Derived Regulatory Cells to T Cells," *Redox Biology* 18 (2018): 54–64, https://doi.org/10.1016/j.redox.2018.06.009.

46. P. D'Acunzo, R. Pérez-González, Y. Kim, et al., "Mitovesicles Are a Novel Population of Extracellular Vesicles of Mitochondrial Origin Altered in Down Syndrome," *Science Advances* 7, no. 7 (2021): abe5085, https://doi.org/10.1126/sciadv.abe5085.

47. S. C. Jang, R. Crescitelli, A. Cvjetkovic, et al., "Mitochondrial Protein Enriched Extracellular Vesicles Discovered in human Melanoma Tissues Can Be Detected in Patient Plasma," *Journal of Extracellular Vesicles* 8, no. 1 (2019): 1635420, https://doi.org/10.1080/20013078.2019.1635420.

48. F. Puhm, T. Afonyushkin, U. Resch, et al., "Mitochondria Are a Subset of Extracellular Vesicles Released by Activated Monocytes and Induce Type I IFN and TNF Responses in Endothelial Cells," *Circulation Research* 125, no. 1 (2019): 43–52, https://doi.org/10.1161/CIRCRESAHA.118.314601.

49. R. A. Eid, M. A. Soltan, M. A. Eldeen, et al., "Assessment of RACGAP1 as a Prognostic and Immunological Biomarker in Multiple Human Tumors: A Multiomics Analysis," *International Journal of Molecular Sciences* 23, no. 22 (2022): 14102, https://doi.org/10.3390/ijms232214102.

50. L. Martin-Jaular, N. Nevo, J. P. Schessner, et al., "Unbiased Proteomic Profiling of Host Cell Extracellular Vesicle Composition and Dynamics Upon HIV-1 Infection," *The EMBO Journal* 40, no. 8 (2021): 105492, https://doi.org/10.15252/embj.2020105492.

51. F. Cocozza, L. Martin-Jaular, L. Lippens, et al., "Extracellular Vesicles and Co-Isolated Endogenous Retroviruses From Murine Cancer Cells Differentially Affect Dendritic Cells," *The EMBO Journal* 42, no. 24 (2023): 113590, https://doi.org/10.15252/embj.2023113590.

52. A. Pfeiffer, J. D. Petersen, G. H. Falduto, et al., "Selective Immunocapture Reveals Neoplastic human Mast Cells Secrete Distinct Microvesicle- and Exosome-Like Populations of KIT-Containing Extracellular Vesicles," *Journal of Extracellular Vesicles* 11, no. 10 (2022): 12272, https://doi.org/10.1002/jev2.12272.

53. M. Durcin, A. Fleury, E. Taillebois, et al., "Characterisation of Adipocyte-Derived Extracellular Vesicle Subtypes Identifies Distinct Protein and Lipid Signatures for Large and Small Extracellular Vesicles," *Journal of Extracellular Vesicles* 6, no. 1 (2017): 1305677, https://doi.org/10.1080/20013078.2017.1305677.

54. A. E. Showalter, A. C. Martini, D. Nierenberg, et al., "Investigating Chaperonin-Containing TCP-1 Subunit 2 as an Essential Component of the Chaperonin Complex for Tumorigenesis," *Scientific Reports* 10, no. 1 (2020): 798, https://doi.org/10.1038/s41598-020-57602-w.

55. J. Mariscal, T. Vagner, M. Kim, et al., "Comprehensive Palmitoyl-Proteomic Analysis Identifies Distinct Protein Signatures for Large and Small Cancer-Derived Extracellular Vesicles," *Journal of Extracellular Vesicles* 9, no. 1 (2020): 1764192, https://doi.org/10.1080/20013078.2020.1764192.

56. A. Rojas-Gómez, S. G. Dosil, F. J. Chichón, et al., "Chaperonin CCT Controls Extracellular Vesicle Production and Cell Metabolism Through Kinesin Dynamics," *Journal of Extracellular Vesicles* 12, no. 6 (2023): 12333, https://doi.org/10.1002/jev2.12333.

57. D. K. Jeppesen, A. M. Fenix, J. L. Franklin, et al., "Reassessment of Exosome Composition," *Cell* 177, no. 2 (2019): 428–445.e18, https://doi.org/10.1016/j.cell.2019.02.029.

58. E. I. Buzas, "Opportunities and Challenges in Studying the Extracellular Vesicle Corona," *Nature Cell Biology* 24, no. 9 (2022): 1322–1325, https://doi.org/10.1038/s41556-022-00983-z.

59. M. Heidarzadeh, A. Zarebkohan, R. Rahbarghazi, and E. Sokullu, "Protein Corona and Exosomes: New Challenges and Prospects," *Cell Communication and Signaling: CCS* 21, no. 1 (2023): 64, https://doi.org/10.1186/s12964-023-01089-1.

60. B. Singh, M. Fredriksson Sundbom, U. Muthukrishnan, et al., "Extracellular Histones as Exosome Membrane Proteins Regulated by Cell Stress," *Journal of Extracellular Vesicles* 14, no. 2 (2025): 70042, https://doi.org/10.1002/jev2.70042.

61. A. Yokoi, M. Ukai, T. Yasui, et al., "Identifying High-Grade Serous Ovarian Carcinoma–Specific Extracellular Vesicles by Polyketone-Coated Nanowires," *Science Advances* 9, no. 27 (2023): ade6958, https://doi.org/10.1126/sciadv.ade6958.

62. E. Panizza, B. D. Regalado, F. Wang, et al., "Proteomic Analysis Reveals Microvesicles Containing NAMPT as Mediators of Radioresistance in Glioma," *Life Science Alliance* 6, no. 6 (2023): 202201680, https://doi.org/10.26508/lsa.202201680.

63. D. Li, W. Lai, Q. Wang, et al., "CD151 Enrichment in Exosomes of Luminal Androgen Receptor Breast Cancer Cell Line Contributes to Cell Invasion," *Biochimie* 189 (2021): 65–75, https://doi.org/10.1016/j.biochi.2021.06.007.

64. S. Keerthikumar, L. Gangoda, M. Liem, et al., "Proteogenomic Analysis Reveals Exosomes Are More Oncogenic Than Ectosomes," *Oncotarget* 6, no. 17 (2015): 15375–15396, https://doi.org/10.18632/oncotarget.3801.

65. A. Stoeck, S. Keller, S. Riedle, et al., "A Role for Exosomes in the Constitutive and Stimulus-Induced Ectodomain Cleavage of L1 and CD44," *The Biochemical Journal* 393, no. pt. 3 (2006): 609–618, https://doi.org/10.1042/BJ20051013.

66. D. L. Turner, D. V. Korneev, J. G. Purdy, A. de Macro, and R. A. Mathias, "The Host Exosome Pathway Underpins Biogenesis of the Human Cytomegalovirus Virion," *eLife* 9 (2020): e58288, https://doi.org/10.7554/eLife.58288.

67. A. L. Graça, M. Gómez-Florit, H. Osório, et al., "Controlling the Fate of Regenerative Cells With Engineered Platelet-Derived Extracellular Vesicles," *Nanoscale* 14, no. 17 (2022): 6543–6556, https://doi.org/10.1039/D1NR08108J.

68. D. Chiasserini, M. Mazzoni, F. Bordi, et al., "Identification and Partial Characterization of Two Populations of Prostasomes by a Combination of Dynamic Light Scattering and Proteomic Analysis," *Journal of Membrane Biology* 248, no. 6 (2015): 991–1004, https://doi.org/10.1007/s00232-015-9810-0.

69. M. F. Baietti, Z. Zhang, E. Mortier, et al., "Syndecan–Syntenin–ALIX Regulates the Biogenesis of Exosomes," *Nature Cell Biology* 14, no. 7 (2012): 677–685, https://doi.org/10.1038/ncb2502.

70. T. Skotland, K. Sagini, K. Sandvig, and A. Llorente, "An Emerging Focus on Lipids in Extracellular Vesicles," *Advanced Drug Delivery Reviews* 159 (2020): 308–321, https://doi.org/10.1016/j.addr.2020.03.002.

71. J. F. Brouwers, M. Aalberts, J. W. A. Jansen, et al., "Distinct Lipid Compositions of Two Types of Human Prostasomes," *Proteomics* 13 (2013): 1660–1666, https://doi.org/10.1002/pmic.201200348.

72. H. Zhang, D. Freitas, H. S. Kim, et al., "Identification of Distinct Nanoparticles and Subsets of Extracellular Vesicles by Asymmetric Flow Field-Flow Fractionation," *Nature Cell Biology* 20, no. 3 (2018): 332–343, https://doi.org/10.1038/s41556-018-0040-4.

73. P. Martínez-Díaz, A. Parra, C. M. Sanchez-López, et al., "Small and Large Extracellular Vesicles of Porcine Seminal Plasma Differ in Lipid Profile," *International Journal of Molecular Sciences* 25, no. 13 (2024): 7492, https://doi.org/10.3390/ijms25137492.

74. S. Tacconi, F. Vari, C. Sbarigia, et al., "M1-Derived Extracellular Vesicles Polarize Recipient Macrophages Into M2-Like Macrophages and Alter Skeletal Muscle Homeostasis in a Hyper-Glucose Environment," *Cell Communication and Signaling: CCS* 22, no. 1 (2024): 193, https://doi.org/10.1186/s12964-024-01560-7.

75. S. H. De Paoli, T. Z. Tegegn, O. K. Elhelu, et al., "Dissecting the Biochemical Architecture and Morphological Release Pathways of the Human Platelet Extracellular Vesiculome," *Cellular and Molecular Life Sciences: CMLS* 75, no. 20 (2018): 3781–3801, https://doi.org/10.1007/s00018-018-2771-6.

76. P. Luo, K. Mao, J. Xu, et al., "Metabolic Characteristics of Large and Small Extracellular Vesicles From Pleural Effusion Reveal Biomarker Candidates for the Diagnosis of Tuberculosis and Malignancy," *Journal of Extracellular Vesicles* 9, no. 1 (2020): 1790158, https://doi.org/10.1080/20013078.2020.1790158.

77. T. Skotland, N. P. Hessvik, K. Sandvig, and A. Llorente, "Exosomal Lipid Composition and the Role of Ether Lipids and Phosphoinositides in Exosome Biology," *Journal of Lipid Research* 60, no. 1 (2019): 9–18, https://doi.org/10.1194/jlr.R084343.

78. K. Trajkovic, C. Hsu, S. Chiantia, et al., "Ceramide Triggers Budding of Exosome Vesicles Into Multivesicular Endosomes," *Science* 319, no. 5867 (2008): 1244–1247, https://doi.org/10.1126/science.1153124.

79. T. Skotland, K. Ekroos, A. Llorente, and K. Sandvig, "Quantitative Lipid Analysis of Extracellular Vesicle Preparations: A Perspective," *Journal of Extracellular Vesicles* 14, no. 3 (2025): 70049, https://doi.org/10.1002/jev2.70049.

80. M. St Germain, R. Iraji, and M. Bakovic, "Phosphatidylethanolamine Homeostasis Under Conditions of Impaired CDP-Ethanolamine Pathway or Phosphatidylserine Decarboxylation," *Frontiers in Nutrition* 9 (2022): 1094273, https://doi.org/10.3389/fnut.2022.1094273.

81. M. Tkach, J. Kowal, A. E. Zucchetti, et al., "Qualitative Differences in T-Cell Activation by Dendritic Cell-Derived Extracellular Vesicle Subtypes," *The EMBO Journal* 36, no. 20 (2017): 3012–3028, https://doi.org/10.15252/embj.201696003.

82. E. W. Deutsch, N. Bandeira, V. Sharma, et al., "The ProteomeXchange Consortium in 2020: Enabling 'Big Data' Approaches in Proteomics," *Nucleic Acids Research* 48, no. D1 (2020): D1145–D1152.

83. W. Huang da, B. T. Sherman, and R. A. Lempicki, "Bioinformatics Enrichment Tools: Paths Toward the Comprehensive Functional Analysis of Large Gene Lists," *Nucleic Acids Research* 37, no. 1 (2009): 1–13, https://doi.org/10.1093/nar/gkn923.

84. J. van Deun, P. Mestdagh, P. Agostinis, et al., "EV-TRACK: Transparent Reporting and Centralizing Knowledge in Extracellular Vesicle Research," *Nature Methods* 14, no. 3 (2017): 228–232, https://doi.org/10.1038/nmeth.4185.

Supporting Information

Additional supporting information can be found online in the Supporting Information section.

Supporting Figure 1: LD and HD samples. Representative photographs of density cushions for L-EVs and S-EVs from HMC-1. The image was created by BioRender.com with permission.

Supporting Figure 2: Higher magnification of TEM electrogram. Representative micrographs are shown for the four EV subtypes from HMC-1 and THP-1. The scale bars represent 200 nm.

Supporting Figure 3: A step-by-step explanation of how the uniquely enriched proteins in each EV subpopulation for Figure 3A-D were calculated.

Supporting Figure 4: Protein groups that have similar expression in all four EV subtypes. The cutoff for a protein to be considered altered in each comparison is a fold change > 1.5 and p-value < 0.05).

Supporting Figure 5: Expression of previously suggested exosome core proteins in subtypes of EVs. The 28 exosomal core proteins suggested by Kugeratski et al (30) were evaluated in our dataset. A multi-group (Anova) comparison was performed in Qlucore and presented here as a heatmap.

Supporting Figure 6: Triton-X controls for the nanoFCM experiments.

Supporting Figure 7: Buffer and antibody controls for the nanoFCM experiments. (A) The buffers used in this project were analysed in the Flow NanoAnlayzer to determine the background. (B) Controls evaluating the background generated by unbound antibody, the autofluorescence by the EVs themselves, and the isotype control for the antibodies were evaluated.

Supporting Figure 8: Controls for double staining for the nanoFCM experiments. To determine that the double staining of the EVs for both ADAM10 and the tetraspanins did not affect the percentage of positive EVs for any of the markers, we compared single and double staining.

Supporting Table 1: Statistics for the multigroup (ANOVA) comparisons performed for Figures 4, 5, and 6.

Supporting Table 2: List of the 107 lipids that we analysed in this study and how they were identified.

Supporting Table 3: Normalized abundance for the 5364 proteins quantified in HMC-1 and THP-1 EVs.